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Stellingen 
1. De hoeveelheid acetylsalicylzuur in de dagelijkse voeding is verwaarloosbaar (dit 
proefschrift). 
2. Er is geen wetenschappelijk bewijs voor de suggestie dat de inname van 
acetylsalicylaat uit de voeding bijgedragen kan hebben aan de afname van sterfte aan 
cardiovasculaire ziekten in de USA (Ingster LM and Feinleib M. Abstract 36th 
Annual Conference on Cardiovascular Disease Epidemiology and Prevention, March 
1996, San Francisco, California, USA; dit proefschrift). 
3. Er is geen wetenschappelijk bewijs voor de stelling dat consumptie van gember de 
thromboxaan-produktie door de bloedplaatjes vermindert (Srivastava KC, Mustafa 
T. Prostaglandins Leukotrienes and Essential Fatty Acids 1989;38:255-66); dit 
proefschrift). 
4. Verplichte soberheid heeft een heilzame uitwerking op de gezondheid (uit: "Cubanen 
blaken van gezondheid dankzij crisis". Volkskrant 7/1/1997). 
5. De eed van Hippocrates is hopeloos verouderd (Intermediair 1996;27:34-35, 37). 
6. De vraag "Hoe gaat het?" is niet geschikt om te achterhalen hoe het werkelijk met 
iemand gaat. 
7. Werksfeer is bij uitstek een onderschatte succes-factor voor produktiviteit, vooral in 
wetenschappelijk onderzoek. 
8. De effectiviteit van een manager wordt meer bepaald door de kwaliteit van zijn/haar 
communicatie, dan door zijn/haar inhoudelijke kennis. 
9 Als je jezelf geen concrete doelen stelt, behoed je jezelf voor mislukkingen, maar 
je ontneemt je ook de kans op succes en ontplooiing. 
10. Significant is niet perse relevant. 
Behorende bij het proefschrift van P.L.T.M.K. Janssen getiteld: 
Dietary non-nutrients and haemostasis in humans: effects of salicylates, flavonoids and ginger. 
Wageningen, 28 mei 1997. 
Voor mam 
"There is a bark of an English tree, which I have found by experience to be a powerful 
astringent, and very efficacious in curing anguish and intermitting disorders. 
The Rev. Mr. Edmund Stone of Chipping-Norton in Oxfordshire, in a letter to the Right 
Honourable George, Earl of Macclesfield, president of the Royal Society, 
April 25, 1763." 
(Weissmann G. Aspirin. Scientific American 1991; January: 58-64.) 
These investigations were carried out at the: 
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The Netherlands 
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Department of Human Biology, 
Maastricht University, 
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The Netherlands 
Department of Haematology, 
Academic Hospital, 
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The Netherlands. 
Abstract 
Dietary non-nutrients and haemostasis in humans: 
effects of salicylates, flavonoids and ginger 
PhD Thesis by P.L.T.M. Karin Janssen, Department of Human Nutrition, Wageningen 
Agricultural University, Wageningen, The Netherlands. 28th May, 1997. 
In this thesis we studied the content of acetylsalicylate and total salicylates in foods, 
and we studied the effects of the dietary non-nutrients salicylates and flavonoids and of 
certain foods on haemostatic parameters in humans. 
Acetylsalicylic acid -aspirin- irreversibly inhibits platelet cyclo-oxygenase, leading 
to decreased platelet thromboxane A2 production and decreased aggregation. Therefore it 
is effective as an anti-thrombotic drug in doses as low as 30 mg/d. Qualitative analyses by 
Swain et al suggested the presence of acetylsalicylate in foods. It was estimated that a 
normal mixed Western diet provides 10-200 mg/d of total salicylate and 3 mg/d of 
acetylsalicylate. We showed in 10 healthy subjects that 3 mg/d of acetylsalicylic acid 
decreased mean platelet thromboxane production by 39±8% (±sd). Thus, quantitative data 
on dietary acetylsalicylate deserved closer investigation. We determined acetylsalicylate and 
total salicylates in 30 foods using HPLC with fluorescence detection. Acetylsalicylate was 
lower than the detection limit (0.02 mg/kg for fresh and 0.2 mg/kg for dried products) in 
all foods. Total salicylates were 0-1 mg/kg in vegetables and fruits, and 3-28 mg/kg in 
herbs and spices. We showed that urinary excretion was a valid indicator for intake of pure 
(acetyl) sal icy lie acid (recovery 77-80%). We then studied urinary salicylate excretion in 17 
subjects eating a variety of diets to estimate the content of bio-available salicylates of diets. 
Median excretion was 1.4 mg/24 h (range 0.8-1.6). Our data suggest that even purely 
vegetable diets provide less than 6 mg/d of salicylates, and no measurable acetylsalicylate. 
These amounts are probably too low to affect coronary heart disease risk, and worries about 
adverse effects of dietary salicylates on the behaviour of children may be unfounded. 
Others found that dietary flavonoids were associated with a reduced risk of coronary 
heart disease and stroke. This might be due to effects on haemostasis, because flavonoids 
have been reported to inhibit platelet aggregation in vitro. We found that concentrations of 
2.5 u,M of the flavone apigenin inhibited collagen- and ADP-induced platelet aggregation 
in vitro by about 26%, whereas the flavonols quercetin and quercetin-3-glucoside had no 
effect. No effects were found on platelet aggregation, thromboxane production, or other 
haemostatic parameters in 18 healthy subjects after they had consumed large amounts of 
quercetin- (onions) and apigenin-rich (parsley) foods daily for 7 d each. We conclude that 
claims for anti-aggregatory effects of flavonoids are based on the in vitro use of 
concentrations that cannot be attained in vivo. Our findings suggest that it is unlikely that 
reported effects of dietary flavonoids on coronary vascular disease risk are mediated 
through platelet aggregation or cyclo-oxygenase activity. Possible effects on known risk 
indicators for coronary heart disease from the coagulation cascade or the fibrinolytic system 
should be examined in a larger study. 
It has been claimed that ginger consumption exerts an anti-thrombotic effect by 
inhibiting platelet thromboxane production. We, however, found no effects on platelet 
thromboxane production in a placebo-controlled cross-over study in 18 healthy subjects 
after consumption of raw (-1±9%, mean±sd) or cooked ginger (1±8%). 
We conclude that contents of (acetyl)salicylate in foods are too low to affect disease 
risk. We could not confirm the putative anti-thrombotic effect of ginger, onions and parsley 
on haemostatic parameters in humans. 
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Chapter 1 
Introduction 
Chapter 1 
Background 
Coronary heart disease is a major health problem in the Western world (1). In 1994, 
about 92,000 people were hospitalized because of this disease, and it was the primary cause 
of more than 20,000 deaths in the Netherlands (2). 
Coronary heart disease is caused by the narrowing of coronary arteries by 
atherosclerotic plaques followed by the formation of a thrombus in an atherosclerotic 
coronary artery, which may lead to an insufficient blood supply. 
Blood platelets play an important role in the development of coronary heart disease: 
injury of endothelial cells in arteries exposes blood to sub-endothelial collagen and tissue 
factor. Collagen activates the enzyme cyclo-oxygenase in platelets to produce thromboxane 
A2, which may cause platelet aggregation and early thrombosis. Aggregation is enhanced 
by the release of ADP from damaged platelets and vessel walls. Platelet-derived growth 
factor stimulates the migration and proliferation of smooth muscle cells and fibroblasts in 
the inner layer of the artery. Fatty streaks are formed, and these can turn into a complicated 
plaque. The plaque narrows the artery lumen, but is also prone to rupture. This, again, 
stimulates platelet aggregation, which can lead to occlusive thrombosis (3-4). 
The activity of cyclo-oxygenase may be inhibited by dietary compounds (5), such 
as dietary non-nutrients, i.e. substances without apparent nutritive value for humans, but 
with pronounced biologic activity (6). This may lead to a decrease in platelet thromboxane 
A2 production and aggregation, and to altered thrombotic tendencies (5). If such anti-
thrombotic substances were present in foods, a diet rich in those non-nutrients might be 
important in coronary heart disease prevention. It has been suggested that dietary 
acetylsalicylate and flavonoids, as well as non-nutrients present in ginger reduce thrombotic 
tendencies by inhibiting platelet cyclo-oxygenase activity (7-12). 
Acetylsalicylic acid, haemostasis and thrombosis 
Acetylsalicylic acid, aspirin, is effective as an anti-thrombotic drug in doses as low 
as 30 mg/d (13-14). It irreversibly inhibits platelet cyclo-oxygenase activity by acetylation 
(15-16). This leads to a decreased conversion of arachidonic acid into platelet thromboxane 
A2 -which is very unstable and is quickly converted into thromboxane B2 (the inactive 
derivate of thromboxane A2)- and to a decreased platelet aggregation (13-16). If 
acetylsalicylic acid were present in foods, a diet rich in acetylsalicylic acid might have an 
anti-thrombotic effect (7-8). 
Data on salicylate contents of foods are scarce (17-20). Based on food analyses and 
urinary excretion data, it was estimated that a normal mixed Western diet provides 10-200 
mg/d of total salicylates (17,20). Those high values were, however, questioned by others 
(18). Qualitative analyses showed the presence of acetylsalicylate in 37 out of 56 foods 
studied (20), but quantitative analyses were absent. It was estimated that a normal mixed 
Western diet provides 3 mg/d of acetylsalicylic acid (17,20; Truswell personal 
communication). It was suggested recently that dietary salicylate intake might have 
contributed to the decline in cardiovascular disease mortality in the USA (8). To study this 
hypothesis data on acetylsalicylate contents of foods and data on effects of foods rich in 
acetylsalicylate on haemostasis in humans are needed. 
Introduction 
Flavonoids, haemostasis and thrombosis 
Flavonoids are polyphenolic compounds that occur ubiquitously in plant foods. Some 
subclasses of flavonoids are flavonols and flavones. Dietary intake of the flavonols 
quercetin, kaempferol and myricetin, and of the flavones luteolin and apigenin in the diet 
was associated with a reduced risk of coronary heart disease and stroke in some but not all 
studies. This association may be explained by the inhibition of LDL-oxidation and/or by 
effects on haemostasis (9-10). Incubations of human platelets or animal cells with isolated 
flavonoids suggest that flavonoids inhibit platelet aggregation, probably by inhibition of 
cyclo-oxygenase activity (10,21-22). It was also suggested that flavonoids may affect 
parameters for coagulation or fibrinolysis (23). However, conflicting observations on the 
effects of flavonols and flavones on in vitro platelet aggregation have been found (21-23). 
Flavonoid concentrations used in in vitro studies range between 10 and 1000 uM (21-22), 
which is 10-1000 times higher than plasma levels reached after oral intake (24). The effects 
of physiological flavonoid concentrations on in vitro platelet aggregation had not been 
studied, and human studies on the consumption of dietary flavonoids on platelet 
aggregation, cyclo-oxygenase activity, and parameters of coagulation and fibrinolysis were 
absent. 
Ginger, haemostasis and thrombosis 
It has been suggested that ginger exerts an anti-thrombotic activity by inhibiting 
platelet aggregation and thromboxane production in vitro (12). However, data on the effects 
of ginger consumption on blood platelet function, especially cyclo-oxygenase activity, are 
scarce and contradictive (25-26). 
Objectives of the project and outline of the thesis 
In this thesis we will focus on the content of total salicylates and acetylsalicylate in 
relevant foods. We will also study the effects of acetylsalicylic acid, flavonoids and ginger 
on haemostatic parameters as indicators for their anti-thrombotic tendency in healthy 
volunteers. Our main question is: Do dietary non-nutrients affect haemostatic parameters 
in humans? To answer this question we divided it into the following sub-questions. 
Acetylsalicylic acid, haemostasis and thrombosis 
What is the effect of 3 mg/d of acetylsalicylic acid (the amount possibly present in 
a normal mixed Western diet) on platelet cyclo-oxygenase activity as assessed by 
thromboxane production in healthy volunteers {Chapter 2)1 
What are the contents of acetylsalicylate and total salicylates in relevant foods 
{Chapter 3)1 
Is the excretion of salicylates in urine a valid marker for intake of pure salicylates? 
What amount of salicylates is excreted in 24-h urine of subjects eating a variety of 
self-selected diets {Chapter 4)1 
What is the estimated amount of bio-available salicylates in diets, based on the food 
analyses and the urinary excretion data? Is this sufficient to prevent coronary heart 
disease {Chapter 3-5)1 
Chapter 1 
Flavonoids, haemostasis and thrombosis 
Does a test tube addition of physiological concentrations of the flavonols quercetin 
and quercetin-3-glucoside and of the flavone apigenin affect in vitro platelet 
aggregation? Does daily consumption of large amounts of onions (quercetin-rich) or 
parsley (apigenin-rich) affect platelet aggregation, thromboxane production, and 
other haemostatic parameters in healthy subjects (Chapter 6)7 
Ginger, haemostasis and thrombosis 
Does daily consumption of raw and cooked ginger affect platelet cyclo-oxygenase 
activity as assessed by thromboxane production in healthy subjects (Chapter 7)1 
The answers to these questions, the conclusions of this thesis and suggestions for 
future research are described in Chapter 8. 
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Abstract 
It has been suggested that certain foods of plant origin contain milligram-quantities 
of acetylsalicylate which could exert an anti-thrombotic effect. Acetylsalicylic acid prevents 
cardiovascular diseases through inhibition of platelet endoperoxyde thromboxane production 
and platelet aggregation. We investigated whether a daily intake of 3 mg acetylsalicylic acid 
causes a measurable decrease of platelet cyclo-oxygenase activity assessed by in vitro 
thromboxane B2 production. We carried out a randomized, double-blind, placebo-controlled 
cross-over study. Ten healthy volunteers (5 men, 5 women) aged 22±3 years (mean±sd) 
participated in the study; there were no drop-outs. Participants took 3 mg/d of 
acetylsalicylic acid or a placebo for 2 weeks each. At the end of each treatment period 
venous blood was drawn, and platelet-rich plasma was stimulated with arachidonic acid. 
Treatment with acetylsalicylic acid caused a 39±8% decrease in maximal thromboxane B2 
production (p=0.000), which was independent of treatment order. Quantitative data on 
acetylsalicylate in foods and the possible anti-thrombotic action of a diet rich in 
acetylsalicylate deserves closer investigation. 
Introduction 
Acetylsalicylic acid is, even in low amounts, effective in the prevention of 
cardiovascular diseases (1-13). It inhibits platelet endoperoxyde thromboxane A2 production 
and platelet aggregation by irreversible acetylation of platelet cyclo-oxygenase which 
converts arachidonic acid into prostaglandin G2/H2, leading to further formation of 
thromboxane A2 (14-16). Low dose of acetylsalicylic acid, however, rarely influences the 
production of endothelial-cell-derived prostacyclin, a vasodilator and inhibitor of 
aggregation (17-22). 
Swain and co-workers suggested that fruits, vegetables, herbs, spices and tea are 
good sources of salicylates. Qualitative results also hinted at the presence of acetylsalicylate 
in fruits, vegetables, beverages, herbs and spices (23-25). The content of acetylsalicylate in 
foods was thought to be 0.1-1.0 mg per 100 g (23,25; Truswell personal communication). 
However, quantitative data on acetylsalicylate in foods are as yet not available. 
In addition to acetylsalicylic acid, flavonoids also inhibit in vitro platelet 
aggregation, but exact mechanisms are poorly understood (26). Intake of certain flavonoids, 
namely flavonols and flavones, is inversely associated with mortality from coronary heart 
diseases (27). The average daily intake of flavonols and flavones in the Netherlands is 23 
mg, mainly provided by tea, apples, onions and red wine (28). 
Data on the anti-thrombotic tendency of a diet rich in acetylsalicylate or flavonoids 
are as yet unknown. We studied whether a daily dose of 3 mg acetylsalicylic acid -the 
amount possibly provided by foods rich in acetylsalicylate- causes measurable changes in 
platelet function in man as assessed by a decrease in thromboxane B2 production. 
Subjects and methods 
Subjects 
Five men and five women, all students, participated in the study. Initial 
characteristics (mean ± sd) were as follows: body mass index 21±1 kg/m2, age 22+3 years, 
platelet count 255±39 *109 platelets/L, and systolic and diastolic blood pressure 116±9 and 
66±7 mm Hg, respectively. All participants were healthy, based on a medical questionnaire, 
with absence of glucose and protein in urine, and with normal blood chemistry 
Low dose acetylsalicylic acid 
(haematocrit, haemoglobin, mean cell volume, erythrocyte sedimentation, alanine amino 
transferase, gamma-glutamyl transferase, creatinine, platelet count, thrombin time, 
prothrombin time, activated partial thromboplastin time). None of the subjects was 
hypertensive. The participants were all non-smokers and had not used any regular or 
homoeopathic medication for at least one month before the study. The subjects were asked 
not to use any medication during the study. Paracetamol was provided to the subjects for 
emergency pain relief, but none of the subjects made use of it. One person used Fucithalmic 
during the study; however there is no indication that this medication should have any 
influence on platelet activity. 
The experimental protocol was approved by the Medical Ethics Committee of the 
Department of Human Nutrition. The protocol was fully explained to the subjects, but they 
were not told that the design of the study was cross-over, so as to minimize possible bias. 
All participants gave their written informed consent. 
Methods 
The study had a double-blind placebo-controlled cross-over design for 2x14 days; 
there was no wash-out period between the treatments. On day 1 the subjects were randomly 
assigned to daily treatment with 3 mg acetylsalicylic acid or a placebo. Four subjects started 
out on acetylsalicylic acid and six on placebo. Subjects swallowed one capsule a day before 
breakfast. Identical capsules of placebo and acetylsalicylic acid were prepared by the 
Department of Pharmacy of the Utrecht Academical Hospital. 
Subjects were requested not to eat fatty fish (salmon, trout, herring, mackerel), and 
to maintain their usual physical activity patterns, alcohol consumption and eating habits. 
Deviations from activity patterns or eating and drinking habits, and consumption of tea, 
fish, licorice, herbs and spices, alcoholic drinks, honey, onions and garlic were recorded in 
a diary, as were any signs of illness. 
Subjects visited the Department on days 0, 7, 15, 21 and 29 to enhance compliance 
and check maintenance of activity patterns and eating and drinking habits. On these visits 
we checked the diary and the body weight, and asked about adverse effects, illness, 
medication and visits to a dentist or doctor. Returned capsules were counted and a new 
supply was distributed. 
Random codes were assigned to all blood samples. Venous blood was drawn into 
3.8% sodium-citrate tubes 1:10 v/v (Sarstedt, Etten-Leur, The Netherlands) on days 11, 14, 
25 and 28 at 8.30 a.m. after an overnight fast. Platelet-rich plasma was prepared by 
centrifugation at room temperature for 10 min at 200 g (Hettich Rotanta, Depex, De Bilt, 
The Netherlands), removed and stored at room temperature in a capped tube. The residual 
blood was centrifuged at room temperature for 10 min at 1500 g to prepare platelet-poor 
plasma. Platelets were counted (Sequoia Turner, Abbot, Santa Clara, USA) and the platelet-
rich plasma was diluted by adding autologous platelet-poor plasma to 250*10' platelets/L. 
The diluted platelet-rich plasma (450 uL) was stimulated in duplicate with arachidonic acid 
(1.5 mM final concentration) (Bio Data Corporation, Horsham, USA) in an aggregometer 
at 37 °C (Bio Data Corporation, Horsham, USA). After 10 minutes 50 uL of the aggregate 
was added to 950 ^L buffer (0.9% NaCl, 0.01 M EDTA, 0.3% bovine gamma-globulin, 
0.005% Triton-X-100, and 0.05% sodium-azide in 50 mM phosphate buffer, pH 6.8; NEN 
Research Products, Du Pont, Boston, USA), the samples were immediately submerged in 
liquid nitrogen, and stored at -80 °C until analysis. Thromboxane B2 was measured in 
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duplicate (Thromboxane B2 [l25I] RIA kit, NEN Research Products, Du Pont, Boston, USA). 
Venous blood, taken from 2 healthy volunteers who had not used any medication for a 
month preceding blood donation, served as control pools. Preparation of the citrate-plasma, 
aggregations and storage were carried out as described. Within-run variation was 8%. 
Data were analyzed using the Statistical Package for Social Sciences (29). Mean 
values of thromboxane production at d 11 and 14, respectively and d 25 and 28, 
respectively were calculated. Those mean values were used to evaluate changes in 
thromboxane B2 production after treatment with acetylsalicylic acid and placebo using a 
paired Student's t-test with a probability level of 5% and a power of 90% for normally 
distributed data; Wilcoxon's Signed Rank Test was used for not normally distributed data. 
Within-person within-period variation of thromboxane production was calculated. Treatment 
order effects were checked using analysis of variance (30). 
Results 
Compliance, expressed by the proportion of capsules not returned, was 100% during 
placebo treatment, and 99% during acetylsalicylic acid treatment. The diaries did not reveal 
relevant changes between the treatment and placebo period in physical activity patterns, 
eating or drinking habits. Body mass index was stable (95%-confidence interval -0.1 to 0.5 
kg/m2) and no adverse reactions were reported. 
There was no effect of treatment order (p=0.207). Within-person variation of 
thromboxane B2 production between blood samples taken 3 days apart was 8% after placebo 
and 10% after aspirin treatment. Consumption of 3 mg/d of acetylsalicylic acid for 14 days 
significantly decreased (p=0.000) platelet thromboxane B, production by 783±77 nmol/10" 
platelets or 39+8% (mean+sd, n=10). Mean thromboxane B2 production was 2016±299 and 
2062±356 nmol/10" platelets after daily treatment with placebo for 11 and 14 days, 
respectively, and 1216+294 and 1294±326 after daily treatment with 3 mg aspirin for 11 
and 14 days, respectively (Fig 1). 
Discussion 
There is a growing interest in food components that affect cardiovascular risk 
through mechanisms other than the classical intermediates, blood pressure and lipoproteins. 
Dietary effects on platelet function are of special interest because acetylsalicylic acid has 
been convincingly shown to reduce the incidence of cardiovascular diseases (7,12,31). 
Contents of acetylsalicylate in foods are unknown yet, and need further investigation. 
As far as we are aware the only previous studies which used a daily dose of 
acetylsalicylic acid in amounts of 3 mg or less were uncontrolled trials (21,32-34). We now 
found that 3 mg acetylsalicylic acid daily reduced in vitro platelet thromboxane B2 
production by almost 40%. By applying careful standardization we were able to reduce the 
combined analytical and biological within-subject variation to 8% after placebo treatment 
and 10%) after aspirin treatment. Using our methodology we may therefore be able to detect 
even a 10% reduction in platelet thromboxane B2 production at p=0.05 with a power of 
90%>, corresponding to the effect of less than 1 mg acetylsalicylic acid daily (21-22). 
According to Swain, fruits, vegetables, herbs, spices, honey, and tea are good 
sources of salicylate and a normal mixed daily diet provides 10-200 mg of total salicylates. 
Low dose acetylsalicylic acid 
Qualitative results also hinted at the presence of acetylsalicylate in fruits, vegetables, 
beverages, herbs, and spices (23,25), but quantitative data are absent. Our data suggest that 
if the content of acetylsalicylic acid in foods were as high as can be inferred from the 
results of Swain et al. (23,25), a normal mixed daily diet might have measurable effects on 
platelet function in man. Studies on the possible anti-thrombotic action of a diet rich in 
acetylsalicylate or flavonoids deserve closer investigation. 
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Fig 1: Maximally stimulated thromboxane B, production (nmol/10" platelets) in 10 healthy volunteers 
treated with placebo (d 11 and 14) or 3 mg/d of acetylsalicylic acid (d 25 and 28) daily, for 2 wks each. 
Treatments were given in random order in a double-blind cross-over trial. Thus 4 out of the 10 subjects 
actually received aspirin on d 1 to IS, and 6 out of the 10 subjects received placebo on d 1 to 15. 
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3.1 Determination of acetylsalicylic acid and salicylic acid 
in foods, using HPLC with fluorescence detection 
Abstract 
We developed a specific and sensitive HPLC method with fluorescence detection for 
the determination of free acetylsalicylic acid, free salicylic acid, and free salicylic acid plus 
salicylic acid after alkaline hydrolysis (free-plus-bound) in foods. Acetylsalicylic acid was 
detected after post-column hydrolysis to salicylic acid. With the method for free 
acetylsalicylic acid and salicylic acid recovery was 95-98% for acetylsalicylic acid added 
to foods, and 92-102% for salicylic acid. Recovery of added salicylic acid was 79-94% for 
the free-plus-bound salicylic acid method. The limit of detection was 0.02 mg/kg for fresh 
and 0.2 mg/kg for dried foods for all substances. We did not find acetylsalicylic acid in any 
of 30 foods previously thought to be high in salicylates. The contents of free-plus-bound 
salicylic acid and of free salicylic acid ranged from 0 to 1 mg/kg in vegetables and fruits 
and from 3 to 28 mg/kg in herbs and spices. Thus the tested foods did not contain 
acetylsalicylic acid and only small amounts of salicylic acid. Our data suggest that the 
average daily intake of acetylsalicylic acid from foods is nil and that of salicylic acid is 0-5 
mg/day. 
Introduction 
Acetylsalicylic acid or 2-acetoxybenzoic acid (Fig 1) are the formal names of a drug 
commonly known as aspirin. Aspirin is effective as a prophylactic against coronary heart 
disease in doses as low as 30 mg/day (1-4). Acetylsalicylic acid may also prevent colon 
cancer (5) and pregnancy induced pre-eclampsia (6). If acetylsalicylic acid were present in 
foods, a diet rich in acetylsalicylic acid might have an anti-thrombotic effect. Not much is 
known about the presence of acetylsalicylic acid in foods. Swain (7) suggested that 
acetylsalicylic acid was present in 37 out of 56 foods studied. However, only qualitative 
data were given, obtained with thin layer chromatography. 
Feingold (8) suggested that the Kaiser-Permanente diet, which eliminates all artificial 
food colours and flavours, as well as foods containing natural salicylates, improves 
behavioral disturbance of children. Although this could not be substantiated in properly 
controlled trials, belief in the efficacy of dietary treatment with salicylate-free diets is firmly 
held (9). 
Hypersensitivity is one of the reported adverse reactions of medication containing 
salicylates, but improvement by a salicylate-free diet is highly unlikely (10). In spite of this, 
there is still much interest in salicylate contents of foods (11). 
The number of publications regarding the content of salicylates in foodstuffs is 
limited and contradictive (12-14). Previous food analyses were performed using HPLC with 
UV detection at 235-245 nm, which is prone to interferences. We therefore adapted an 
HPLC method with fluorescence detection (15) for food analysis and measured free 
acetylsalicylic acid, free salicylic acid and free-plus-bound salicylic acid, i.e. free salicylic 
acid plus salicylic acid after alkaline hydrolysis, in 30 common foods previously reported 
to contain salicylates. 
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ACETYLSALICYLIC ACID 
Figure 1: Structure of acetylsalicylic acid and salicylic acid. 
SALICYLIC ACID 
Materials and methods 
Foods and sample preparation 
We selected foods that were earlier reported to have a high content of salicylic acid 
and/or are known to be consumed in large amounts. 
We purchased 3 samples of 500 g of each type of fresh fruit or vegetable at different 
local supermarkets in the summer of 1994. Fresh foods were processed within 24 h, non-
edible parts were removed and the 3 samples were combined per product to a composite 
sample by mixing equal amounts. One packing of each of 3 different brands of processed 
foods was purchased, again in local supermarkets in the summer of 1994, and combined to 
a composite sample. 
Fresh and canned foods were chopped under liquid nitrogen immediately after 
cleaning. The frozen samples were ground using a food processor, and extracted 
immediately. None of the samples were freeze-dried because of the risk of sublimation of 
the salicylic acid. Dried foods were ground without pretreatment. 
We prepared tea from 1500 mL of boiling water and 3 tea bags of different brands 
each containing 4 g of tea. Tea bags were removed after 5 min, and the liquid was allowed 
to cool. We prepared coffee by pouring 1 L of boiling water on 50 g of a mixture of 3 
brands of ground coffee contained in a paper filter. The liquid was allowed to cool. 
Extraction and hydrolysis 
Samples were protected from direct daylight during the entire extraction procedure 
(Fig 2). We weighed out 10.00 g of the freshly ground fresh foods or 1.00 g of the dried 
foods and added 9 mL of water to the dried foods. 
Determination of free acetylsalicylic acid and salicylic acid 
Samples were homogenized with 20 mL of acetonitrile/water/acetic acid (25/75/5) 
for 30 s in a Waring Blender at high speed and sonicated for 5 min. 
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Free-plus-bound salicylic acid 
We essentially followed the method of Swain (7): food samples were mixed with 
10 mL of NaOH (250 g/L) for 1 h on a rotary-shaker (New Brunswick Sc), at 250 rpm. 
Extracts were left to stand overnight at room temperature, shaken for 1 h, acidified to pH 
1-2 with 10 M HCl, and transferred quantitatively with water into a liquid/liquid extractor 
(Fig 3). The extractor was placed onto a heated flask, and diethyl ether was added in the 
extractor until about 50 mL flowed over into the heated flask. We extracted the samples on 
2 successive days for 6 h each day. Diethyl ether was evaporated carefully until almost dry, 
and the last bit of ether was evaporated at room temperature, to avoid sublimation of 
salicylic acid. The residue was taken up in 25 mL of acetonitrile/water/acetic acid (25/75/5) 
and sonicated for 5 min. 
We filtered approximately 2 mL of each sample extract through a 0.45 i^m filter for 
organic solvents (Acrodisc CR) prior to injection into the HPLC system. 
Free-plus-bound salicylic acid 
Food sample 
freeze in liquid nitrogen 
cut, pool and homogenize 
\ 
Free acetvlsalicvlic and salicylic acid 
10 g of sample 
add 10 mL 25% NaOH 
10 g of sample 
20 mL acetonitrile/water/acetic acid 
(25/75/5) 
shake 1 h 
let stand overnight 
shake 1 h 
acidify pH 1-2 
liquid/liquid extraction 
with diethylether for 12 h 
(Fig 3) 
evaporate 
take up residue in 
acetonitrile/water/acetic acid 
(25/75/5) 
homogenize for 30 sec 
5 min ultrasonic bath 
i 
filtration 0.45 urn 
inject into HPLC 
Figure 2: Methods for extraction of free-plus-bound salicylic acid and of free acetylsalicylic and salicylic 
acid. 
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Standards 
Acetylsalicylic acid (Sigma A-5376) and salicylic acid (Sigma S-0875), were 
dissolved in acetonitrile/acetic acid (99/1) to a concentration of 1 g/L. Acetylsalicylic acid 
standards were made daily and salicylic acid standards once a week. Further dilutions were 
made daily in acetonitrile/water/acetic acid (25/75/5) which is similar to the eluent, thus 
preventing injection problems. Calibration curves were constructed in the range of 2-20 
/ug/L for acetylsalicylic acid and 10-300 /xg/L for salicylic acid. We identified the peaks by 
comparing retention times of samples with those of standards. Occasionally, peaks were 
confirmed by addition of standards to the sample extracts. 
condensor 
diethylether 
WL diethylether 
sample 
boiling diethylether 
heater 
Figure 3: Liquid/liquid extraction apparatus for the continuous water/diethyl ether extraction of 
salicylic acid from hydrolysed food samples. Acidified liquid sample after alkaline hydrolysis is 
introduced into A. Diethyl ether is added in A until flask B contains 50 mL. Heating is started after 
connecting the extractor with the condenser. 
Chromatography 
The HPLC system consisted of a Perkin-Elmer ISS-100 automatic injector, a 
Gynkotek 480 pump, a Lichrospher RP-18 (Merck) column (4 x 250 mm, 5 urn) protected 
by a Perisorb RP-18 (3.9 x 40 mm, 30-40 urn) precolumn both placed in a column oven 
set at 30°C, a fluorescence detector (Merck Hitachi F-1050) with excitation wavelength at 
300 nm, and emission wavelength at 400 nm, and a post-column stainless steel reaction coil 
(0.5 x 5000 mm) immersed in a glycerol-filled bath set at 60°C. Acetylsalicylic acid and 
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salicylic acid were separated with an eluent consisting of methanol/water/phosphoric acid 
85% (40/60/0.2), at a flow rate of 0.9 mL/min. Acetylsalicylic acid was hydrolysed to 
salicylic acid in the post-column reactor by addition of 0.15 mL/min of 1 M NaOH to the 
eluent using a Gilson minipuls-3 pump. 
Results 
The salicylates in foods are partly bound as esters or glycosides (16). We used 
alkaline hydrolysis plus ether extraction to liberate matrix-bound salicylates and to convert 
salicylate esters and glycosides to their parent salicylic acid. Values thus obtained were 
named "free-plus-bound salicylic acid". Acetylsalicylic acid is unstable in alkali. We 
therefore used a gentle extraction to detect acetylsalicylic acid; this technique also detects 
the extractable or "free" salicylic acid. Contents were measured with an optimized HPLC 
method with fluorescence detection. 
Optimization of column and eluent 
We tested a Novapak RP-18, 150 x 3.9 mm, 4 um column (Waters Associates, 
Milford MA), a Lichrospher RP-18, 250 x 4 mm, 5 urn column (Merck), and a Inertsil 
ODS 2, 150 x 4.6 mm, 5 urn column (GL Sciences Inc.) with UV detection at 245 nm. 
Dissociation of salicylic acid (pKa=3.0) is an important variable in its chromatographic 
behaviour. We therefore tested acetic acid and phosphoric acid as eluent acidifiers, taking 
care that the pH of the eluent remained between 2.2 and 2.4. Methanol/water and 
acetonitrile/water both with acetic acid or phosphoric acid were used. 
The Inertsil column showed low plate numbers for both acetylsalicylic acid 
(N=3,200) and salicylic acid (N=5,700) with acetonitrile/water/phosphoric acid. Therefore 
it was not tested with any of the other eluents. Acetylsalicylic acid showed symmetric peaks 
on the Novapak and the Lichrospher column with all eluents, but salicylic acid showed 
variable degrees of peak tailing. The Lichrospher column was superior for both 
acetylsalicylic acid (N=l 1,200) and salicylic acid (N=l 1,500) with all mobile phases. 
Phosphoric acid was more compatible with the post-column reaction than acetic acid, 
because a lower amount of sodium hydroxide was required to neutralise it. We therefore 
chose methanol/water/phosphoric acid as a mobile phase and the Lichrospher as a column 
(Fig 4a). 
Post-column hydrolysis 
Acetylsalicylic acid can be made fluorescent by conversion to salicylic acid. Post-
column hydrolysis conditions were essentially as described by Siebert and Bochner (15), 
but the use of 0.2% instead of 0.1% of phosphoric acid in the eluent and 1 M instead of 0.5 
M NaOH resulted in somewhat better plate numbers. 
Acetylsalicylic acid hydrolysis was complete at 60 °C using a coil of 0.5mm x 5m 
and addition of 0.15 mL/min of 1 M NaOH. Salicylic acid proved to be stable under these 
conditions. Excitation was at 300 nm and emission at 400 nm. The fluorescence of salicylic 
acid was about 8 times higher at alkaline than at acid pH. Phenolic compounds that possibly 
interfere in UV detection, such as cinnamic and hydroxybenzoic acids, showed little 
fluorescence under these conditions. The sensitivity of the fluorescence detection of salicylic 
acid was about a factor 1000 higher than that by ultraviolet light absorption at 235-245 nm. 
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Figure 4: Typical chromatograms of acetylsalicylic acid and salicylic acid in foods. 
Peaks: ASA, acetylsalicylic acid; SA, salicylic acid. Arrows indicate retention time of acetylsalicylic acid: 
a=standards, b=tea extract, c=wine, d=thyme. Detection: fluorescence after post-column hydrolysis of 
acetylsalicylic acid; excitation, 300 nm; emission, 400 nm; flow rate: eluent, 0.9 niL/min; sodium 
hydroxide 1 IM, 0.15 mL/min. 
Stability of acetylsalicylic acid and salicylic acid 
The stability of acetylsalicylic acid in various extraction solvents was tested by 
comparing UV spectra of the solutions. The UV absorbance maximum in eluent of salicylic 
acid is 303 nm and that of acetylsalicylic acid is 275 nm. Acetylsalicylic acid hydrolysed 
rapidly to salicylic acid when dissolved in methanol. The stability was better in the presence 
of acetic acid plus methanol or acetonitrile (Table 1). 
Salicylic acid was stable for more than 1 week in all solvents if kept in the dark, as 
judged by its unchanged UV-spectrum. We never observed any degradation of 
acetylsalicylic acid or salicylic acid in the HPLC elution pattern. 
Sample extraction and hydrolysis 
Free acetylsalicylic acid and salicylic acid 
Acetylsalicylic acid added as a solution in acetonitrile to samples showed a recovery 
ranging from 95-98% (Table 2) and for added free salicylic acid from 92-102% (Table 3). 
Recoveries did not change after extracts had been stored for 24 h. 
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Table 1: Stability of acetylsalicylic acid in various 
solvent 
methanol 
methanol 
methanol/1% acetic acid 
acetonitrile/1% acetic acid 
acetonitrile/water/acetic acid (25/75/5) 
acetonitrile/water/H3P04 (25/75/0.2) 
solvents. 
time 
4 h 
1 d 
5 d 
5 d 
5 d 
5d 
loss (%) 
7 
22 
2 
3 
2 
3 
a
 All determinations are based on single sample analysis; concentrations during storage 
were 1 mg/mL, and during measurement 20 pg/mL, except for acetylsalicylic acid in 
water where we used a saturated solution. 
Table 2: Recovery of acetylsalicylic acid when added to various foods. 
product 
grape 
tomato 
thyme 
acetylsalicylic 
amount in food 
(mg/kg) 
<0.02 
<0.02 
<0.02 
acid 
amount added 
(mg/kg) 
0.075 
0.077 
0.150 
recovery 
(%) 
98 
98 
95 
a
 Means of duplicate analyses, except for thyme which was analyzed in quadruplicate. 
Free-plus-bound salicylic acid 
We extended the ether extraction as used by Swain (14) to 12 h, because extraction 
was not complete after 5 h (Table 4). This was probably due to a less efficient construction 
of our extraction apparatus (Fig 3). After the first 12 h of extraction, a new flask with 50 
mL of ether was placed on the extraction apparatus and the ether was refluxed for an 
additional 3 h. This extension of the extraction period added little to the salicylic acid yield: 
the gain was 0% for wine and 5% for thyme. 
In the free-plus-bound method acetylsalicylic acid was completely hydrolysed to 
salicylic acid. Methylsalicylate, a flavourant, was also hydrolysed completely. 
The mean free-plus-bound salicylic acid content of a sample of freeze-dried endives 
analyzed on 6 different days was 0.132 mg/kg; the coefficient of variation between days 
was 8%. Recovery of salicylic acid added as a solution in acetonitrile to samples in the 
free-plus-bound method ranged from 79-94% (Table 2). 
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Determination in foods 
N o acetylsalicylic acid was detected in any of the food samples (Table 5). Salicylic 
acid was frequently detected in vegetables and fruits though in concentrations of only 0-1 
mg/kg. Some herbs and spices like thyme, rosemary and cinnamon contained amounts up 
to 28 mg/kg. The poor duplicates of the tomato sample (Table 4) may be due to the fact 
that the sample was not homogeneous; pits and peel were very difficult to grind. 
Figure 4 shows some typical chromatograms of the separation of salicylic acid and 
acetylsalicylic acid in various foods. 
Table 3: Recovery of salicylic acid when added to various foods.' 
product 
brewed tea 
grape 
tomato 
thyme 
amount of 
free-plus-
bound 
salicylic acid 
in food 
(mg/kg) 
0.500 
0.032 
0.225 
16.1 
amount of 
salicylic acid 
added (mg/kg) 
0.400 
0.075 
0.200 
10.0 
recovery (%) 
free 
salicylic 
acid 
method 
99 
102 
102 
92 
free-plus-
bound 
salicylic acid 
method 
90 
79 
94 
Means of duplicate analyses, except for thyme which was analyzed in quadruplicate; 
for methods see text. 
Table 4: Influence of extraction time on the amounts of salicylic acid extracted from different foods by 
the free and free-plus-bound methods. 
free-plus-bound salicylic acid 
(mg/kg) 
product free salicylic acid (mg/kg) 
grape <0.02 
tomato 0.05 
thyme no determination 
5 h 
0.020 
0.236 
12.05 
12 hD 
0.028 
0 .276 c 
15.85 
Means of duplicate determinations. 
' After 5 h new solvent in heated flask; cf Materials and Methods. 
Poor duplicate, sample possibly not homogeneous. 
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Discussion 
We found that foods previously reported to be important sources of salicylic acid 
and potential sources of acetylsalicylic acid (7,14), contained low amounts of salicylic acid 
and no acetylsalicylic acid. We used a sensitive and specific HPLC method with post-
column hydrolysis of acetylsalicylic acid and fluorescence detection optimized for the 
determination in foodstuffs. For the acetylsalicylic acid content in foods, we used a fast 
extraction into a solvent in which acetylsalicylic acid was stable. The solubility of 
acetylsalicylic acid in the solvent was sufficient, so that any free acetylsalicylic acid present 
in the food sample would be extracted. 
None of the 30 products tested by us contained measurable amounts of 
acetylsalicylic acid. Swain (7) tested 56 foods with a qualitative thin layer chromatographic 
method and found acetylsalicylic acid in 14 and both acetylsalicylic acid and salicylate in 
23. The identity of the acetylsalicylate spot on the thin layer plate was confirmed by co-
elution of a standard and by the slow hydrolysis to salicylic acid that occurred on the thin 
layer plate. Swain extracted acetylsalicylic acid by alkaline extraction for 2 h (17). In our 
hands all acetylsalicylic acid was hydrolysed completely to salicylic acid under those 
conditions. 
Swain et al (14) found salicylic acid contents ranging from 0 to 60 mg/kg in 
vegetables and fruits and from 0 to 2180 mg/kg in condiments. Other investigators found 
much lower contents: Robertson and Kermode (13) found salicylic acid in the range of 
0.01-0.82 mg/kg in vegetables and fruits, and Herrmann (16), using a less sensitive method, 
found only traces of salicylic acid in vegetables and fruits. Herrmann (16) also determined 
the presence of salicylates in herbs and spices and found contents of 0-81 mg/kg (Table 5) 
and questioned the high values found by Swain (7,14). Differences might arise by 
differences in origin, processing or storage. Therefore, we measured salicylates in composite 
samples of 3 different origins or brands. Swain did find a high natural variation amounting 
to 10-fold differences. However, all our results are much lower than the lowest value given 
by Swain. This excludes natural variation as a possible explanation for these discrepancies. 
Discrepancies in salicylate contents between extraction methods may arise through 
differences in the extent of liberation of matrix-bound salicylates. However, though we used 
essentially the same extraction method as Swain we found much lower contents. Possibly 
the HPLC separation and UV detection of Swain was not specific enough and some other 
component co-eluted at the same time as salicylic acid. 
Muller and Fugelsang (18) published salicylic acid contents in red wine of 11-21.5 
mg/L. Again we believe that these values are too high (19). In 4 wine samples from 
different countries we found 0.26-0.71 mg/kg. This agrees with data of Robertson (20) of 
0.04 mg/kg in grapes and 0.08 mg/kg in fermented juice. 
Little free salicylic acid is present in fresh products because salicylate is bound as 
ester or as glycoside (12). In most of the processed products salicylic acid apparently was 
liberated by food processing. 
The difference in the amounts of free salicylic acid and free-plus-bound salicylic 
acid for peppermint (Table 5) is probably due to methylsalicylate used as a flavourant. 
Some herbs and spices contain rather high amounts of salicylic acid, but their 
consumption is low. Using the food intake data of the Dutch Food Consumption Survey 
(21) and our data of free-plus-bound salicylic acid, we estimate the intake of salicylates in 
the Netherlands 0-5 mg/d. 
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Our data suggest that the acetylsalicylic acid and the salicylic acid content in a 
normal mixed daily diet may be too low to produce measurable physiological effects in 
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3.2 No aspirin in red wine 
Muller and Fugelsang (1) suggest that wine is a good source of salicylic acid and 
that this may explain a preventive effect in cardiovascular diseases. We measured salicylic 
and acetylsalicylic acid in red Bordeaux wines (Rineau 1993, Lavergne 1993, and 
Mondetour 1992) using HPLC and a highly specific fluorescence detection method. The 
method was validated by varying extraction conditions, mainly extraction solvents and 
extraction time. In red wine we found 0.7 mg salicylic acid per litre and no acetylsalicylic 
acid (detection limit 0.025 mg/L). Thus, by contrast with Muller and Fugelsang (1) we 
found negligible amounts of (acetyl)salicylic acid in wine. Even if wine did contain larger 
amounts of salicylic acid this would not be expected to affect cardiovascular risk. Salicylic 
acid and dihydroxybenzoic acids do not affect thromboxane formation and platelet 
aggregation; this specifically requires acetylsalicylate (aspirin), which inactivates cyclo-
oxygenäse by irreversible acetylation (2). 
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Urinary salicylate excretion 
in subjects eating a variety of diets shows 
that amounts of bio-available salicylates 
in foods are low 
Janssen PLTMK, Hollman PCH, Reichman E, Venema DP, 
van Staveren WA, Katan MB. 
Urinary salicylate excretion in subjects eating a variety of diets 
shows that amounts of bio-available salicylates in foods are low. 
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Abstract 
Intake of acetylsalicylic acid reduces the risk of cardiovascular disease, and is 
associated with a decreased risk for colorectal cancer. Amounts of salicylates in foods are 
thus of interest, but data are scarce and controversial. We gave 58 umol (10.5 mg) pure 
acetylsalicylic acid or 66 umol (9.1 mg) salicylic acid to 6 volunteers and recovered 77-
80% in 24-h urine samples. Thus, urinary excretion is a valid indicator for intake of free 
forms of (acetyl)salicylic acid. In order to estimate the bio-available salicylate contents of 
diets, we subsequently studied salicylate excretion in 17 volunteers from 14 countries and 
4 continents who ate a wide variety of self-selected diets. Median 24-h urinary salicylate 
excretion was 10 umol (range 6-12). Values increased with the fibre content of the diet 
(r=0.73), suggesting that vegetable foods are the main sources of salicylates. However, 
amounts of salicylates in a variety of diets are evidently low and probably insufficient to 
affect disease risk. 
Introduction 
Acetylsalicylic acid, aspirin, has a variety of biological effects. It is effective in the 
prevention of cardiovascular disease in doses as low as 30 mg/d (1-3). Intake has also been 
associated with a decreased risk for colorectal cancer (4-5). Feingold (6) suggested that the 
intake of dietary salicylates causes hyperactivity in children, but this could not be 
substantiated in properly controlled trials (7-8). 
Plants contain natural salicylates, but data on the salicylate contents of foods are 
scarce and controversial (9-15; AR Swain, RH Lobley, AS Truswell, unpublished 
observations, 1985). Swain et al (13-14) suggested that a normal mixed diet provides 72-
1448 (imol/d (10-200 mg/d) of total salicylates, and significant but unknown amounts of 
acetylsalicylate. In contrast, we (15-16) found total salicylate contents of only 0-0.7 
umol/100 g (0-0.1 mg/100 g) in vegetables and fruits, and 2-20 umol/100 g (0.3-2.8 
mg/100 g) in herbs and spices. We could not confirm the presence of acetylsalicylate in any 
of the 30 Dutch products studied; the limit of detection was 0.1 umol/kg (0.02 mg/kg) for 
fresh, and 1.4 umol/kg (0.2 mg/kg) for dry products. Uncertainties about concentrations of 
salicylates in the diet may arise because of a limited selection of foods or differences in 
analytical techniques; for instance liberation of salicylates from a plant matrix is notoriously 
difficult. Acetylsalicylate is excreted in urine mainly as various salicylates (17-18). Swain 
et al (13; AR Swain, RH Lobley, AS Truswell, unpublished observations, 1985) showed 
that this is also the case with other salicylates in foods. 
We therefore assessed the validity of using excretion of salicylates in urine as a 
marker for salicylate intake. We then investigated the urinary excretion of salicylates in 
subjects with a wide range of dietary habits to estimate the bio-available salicylate contents 
of human diets. 
Subjects and methods 
Subjects 
Six Dutch women working at our university participated in a preliminary study to 
check the validity of urinary salicylates as a marker of intake. These control subjects were 
aged 27±4 y and ate a normal mixed Western diet. 
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We next recruited volunteers from the town and surroundings of Wageningen. We 
sought nonresidents from foreign countries and Dutch subjects eating nontraditional diets 
to maximize the chances of encountering a wide range of salicylate intakes. All applicants 
had to speak English or Dutch. Twenty-nine volunteers responded to posters in university 
buildings, apartments, shops, ethnic restaurants, and community centres for foreigners. We 
excluded one applicant because she was pregnant, five because their dietary habits deviated 
too much from their native habits, one because she used medication, and another five at 
random. Six men and 11 women aged 29+7 y (mean±sd) with a mean body mass index (in 
kg/m2) of 21+3 participated in the study. They habitually ate a wide variety of diets (Table 
1). Thirteen subjects came from abroad and most of them were temporarily living in the 
Netherlands; four were Dutch. 
All subjects were healthy on the basis of a medical questionnaire and negative 
checks for urinary protein and glucose. They did not smoke and had not used any regular 
or homoeopathic medication or dietary supplements for at least 1 mo before the study, 
except for 7 women who took oral contraceptives. We instructed subjects to use no dietary 
supplements or medication during the study; only the use of oral contraceptives was 
permitted. We supplied them with Naproxen (naproxenum; Pharmachemie BV, Haarlem, 
The Netherlands), which is a salicylate-free pain medication. 
The protocol was approved by the Medical Ethics Committee of the Wageningen 
Agricultural University Department of Human Nutrition. We explained the protocol fully 
to the subjects who gave their written informed consent. 
Methods 
The 6 control subjects of the validation study participated in a randomized cross-over 
study for 3 d separated by washout periods of 14 d. They swallowed an indistinguishable 
capsule containing pure salicylic acid or acetylsalicylic acid, or nothing as a placebo 
together with a/?ara-aminobenzoic acid capsule. On analysis, capsules contained 58±1 umol 
(10.510.2 mg; n=3) acetylsalicylic acid, 66±2 umol (9.110.2 mg; n=3) salicylic acid, or 
78.210.6 mgpara-aminobenzoic acid (n=3). The 17 subjects with unusual diets participated 
in the study for 1 d. 
We visited the 6 subjects participating in the validation study and the 17 subjects 
with the different diets at their homes and explained the protocol. We provided them with 
bottles to sample urine and herbs and spices that they used in cooking. We also gave them 
a box containing dry ice, a household scale, a diary, and 3 capsules containing para-
aminobenzoic acid which served to check the completeness of the 24-h urine samples (19). 
The day after this visit participants swallowed the first capsule of />ara-aminobenzoic 
acid just before breakfast, the second before lunch, and the third before dinner. They 
collected urine for 24 h from the time they swallowed the first capsule. The volunteers 
collected each urine sample in a separate bottle containing 0.225 g of thimerosal (T5125; 
Sigma, Axel, The Netherlands) as a preservative. They wrote the times of urine collections 
on each bottle, and put filled bottles on dry ice immediately. The 6 subjects of the 
validation study and the 17 subjects eating their specific diets maintained their usual eating 
and drinking habits during the study day. 
All subjects weighed and recorded in a diary all foods and drinks they consumed 
during the days of urine collection. They saved samples of all herbs and spices in amounts 
equal to those that they had used that day. They put dried herbs and spices in plastic bottles 
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and fresh ones on dry ice. Subjects recorded in the diary any signs of illness, medications 
used, and times at which they had swallowed the capsules. 
A trained dietician (ER) checked the food records at the subjects' homes on day 2. 
She asked about possible deviations from dietary habits, adverse effects, illness, medications 
and visits to a dentist or doctor, and collected the urine samples and herbs and spices. We 
assigned random codes to the urine samples and stored them at -20 °C. We weighed the 
samples of herbs and spices. 
We weighed the thawed 24-h urine samples and pooled them per subject. We took 
10 mL aliquots of the 24-h pools, and stored the samples at -20 °C until analyzed. 
We determined concentrations of total salicylates in the 24-h pools after hydrolysis 
with 5 M HCl for 2 h at 120 °C according to Swain (13). The residue of the ether-extract 
was taken up in 1.5 mL acetonitrile:water:acetic acid (25:75:5, by vol) and filtered through 
a 0.45 (xm filter for organic solvents (Acrodisc CR PTFE; Gelman Sciences, Ann Arbor, 
MI). We injected 10 uL onto a Lichrospher 100 RP18 (Merck, Darmstadt, Germany) 
column (4.6x250 mm, 5-um particle size) by using methanol:water:phosphoric acid 85% 
(40:60:0.2, by vol) as the mobile phase at a flow rate of 0.9 mL/min. The eluent was mixed 
with 0.15 mL 1 mol NaOH/L per min in a post-column stainless steel reaction coil (0.5 mm 
x 5 m) placed in a waterbath at 60 °C. Fluorescence was measured at 400 nm with a Merck 
Hitachi F-1050 (Tokyo) fluorescence detector with the excitation wavelength set at 300 nm. 
A urine control sample was included in each series of analyses; the relative SD of the 
between-run variation was 9%, and of the within-run variation 2%. The limit of detection 
was 0.1 umol/kg (0.02 mg/kg) urine. 
We measured joara-aminobenzoic acid photometrically using fiuorescamine (F9015; 
Sigma, Axel, The Netherlands) after hydrolysis of urine samples with 0.7 M HCl for 40 
min at 100 °C (20). 
Recoveries of salicylates in the validation study with salicylic acid and 
acetylsalicylic acid supplementation were corrected for salicylate excretion with placebo. 
We calculated the intake of energy and nutrients of the 17 subjects eating unusual 
diets using the Netherlands Nutrient Data Bank NEVO (21), and calculated the daily intake 
of herbs and spices using the weights of the duplicate portions. We did not calculate the 
food intake of the 6 participants in the validation study. 
To estimate the range of salicylate intake we calculated the intake of dietary 
salicylate of 2 subjects having the highest (nos. 6 and 14; Table 1) and 2 having the lowest 
(nos. 10 and 16; Table 1) excretion of salicylates using their food records and salicylate 
concentrations of foods as determined by Swain et al (13-14), Robertson and Kermode (11), 
Herrmann (10), and Janssen et al (15), and Venema et al (16). 
Results 
Two subjects (nos. 1 and 7; Table 1) were unwilling to take /»ara-aminobenzoic 
acid; the other 15 and the 6 subjects of the validation study stated that they had swallowed 
all capsules of /?ara-aminobenzoic acid. Mean recovery of para-aminobenzoic acid in the 
24-h urine pools was 80+14% (meanlsd) in the 15 diet study subjects and 86+10% in the 
6 validation study subjects. 
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Mean recovery of administered acetylsalicylic or salicylic acid in 24-h urine of the 
6 validation study subjects was 80±18% for salicylic acid and 77±10% for acetylsalicylic 
acid (Fig 1). Median salicylate excretion was 10 umol/24 h, with a range of 6-12 umol/24 
h (1.4 mg/24 h, range: 0.8-1.6 mg/24 h) for the 6 subjects (Fig 1) on the day they took no 
salicylic or acetylsalicylic acid. 
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Fig 1: Urinary excretion of salicylates in 6 healthy volunteers participating in a randomized validation 
study lasting 3 d, separated by washout periods of 14 d. On each urine collection day subjects 
swallowed a capsule containing 66 + 2 jimol (9.1 + 0.2 mg) of pure salicylic or 58+1 /imol (10.5+0.2 mg) 
of acetylsalicylic acid, or nothing as placebo. Each symbol represents a different subject. To convert 
salicylate values to mg/24 h, multiply by 0.13812. 
In the 17 subjects with nontraditional diets, energy intake was 9.0+3.1 MJ (range: 
3.8-16.9 MJ), of which 15±4% (range: 10-24%) was provided by proteins, 51+12% (range: 
31-71%) by carbohydrates, and 33±10% (range: 13-47%) by fats; only 2 of the 17 subjects 
consumed alcohol (nos. 3 and 13; Table 1). Median intake of vegetable proteins was 7% 
of total energy intake (range: 4-12%), and intake of dietary fibre was 1.7 g/MJ (range: 0.6-
5.7 g/MJ) (Fig 2). 
Median excretion of salicylates in urine for the 17 subjects eating unusual diets was 
10 umol/24 h (1.4 mg/24 h), with a range of 4-34 umol/24 h (0.5-4.7 mg/24 h; Fig 2). 
Salicylate excretion correlated positively with intake of dietary fibre (r=0.73. p<0.01) and 
with intake of protein from vegetable sources (r=0.42, p=0.10). 
Calculations of the intake of dietary salicylates of 4 subjects (nos. 6, 10, 14, and 16; 
Table 1) by using salicylate contents of foods as determined by Swain et al (13,14) 
produced intake values that were 2 to 18-fold higher than the amounts excreted in urine 
(Table 2). Calculating the intake of dietary salicylate using salicylate contents of foods as 
determined by us (15,16) or others (10,11), revealed lower values (Table 2). 
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Fig 2: Urinary excretion of salicylates versus intake of dietary fibre in 17 healthy volunteers eating a 
variety of self-selected diets. To convert salicylate values to nig/24 h, multiply by 0.13812. 
Table 2: Excretion of salicylates in urine of 4 healthy volunteers eating an Indian (no. 6), Malaysian 
(no. 10), "prehistoric" (no. 14), or Surinamese (no. 16) diet, respectively. 
subject 
6 
10 
14 
16 
urinary 
salicylates 
((.imol/24 h) 
34 
4 
23 
5 
estimated 
Swain 
et al 
(13-14) 
62 
54 
211 
83 
intake of dietary 
Robertson 
and 
Kermode 
(11) 
0 
0 
1 
1 
salicylates ()jmol/24 h) 
Herrmann 
(10) 
1 
1 
5 
3 
Janssen 
et al 
(15-16) 
2 
2 
4 
3 
Subjects weighed and recorded all foods and drinks consumed during the urine-collection day in a 
diary and sampled equal amounts of the herbs and spices they used that day. 
We calculated the intake of dietary salicylates using the food records, the weights of the herbs and 
spices consumed, and salicylate contents of foods as determined by Swain et al (13-14), Robertson and 
Kermode (11), Herrmann (10), and Janssen et al (15-16). To convert salicylate values to mg/24 h, 
multiply by 0.13812. 
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Discussion 
We found that subjects eating self-selected diets high in a variety of plant foods 
excreted only a few milligrams of salicylates per day (Fig 1-2). When we gave subjects 
small amounts of pure acetylsalicylic or salicylic acid we recovered about 80% in urine 
(Fig 1). 
Our assay only measures salicylates and its conjugates. However, a small fraction 
of the salicylates is metabolized to gentisic acid, which would escape detection (18). Thus 
urinary excretion is a valid marker for intake, even at low amounts. Our recoveries of para-
aminobenzoic acid indicate that the 24-h urine samples were nearly complete. 
Our results are at variance with those of Swain et al (13; AR Swain, RH Lobley, AS 
Truswell, unpublished observations, 1985). They reported urinary salicylate excretions of 
825±43 umol/24 h (114±6 mg/24 h; meanlsem, n=25) after consumption of a diet 
providing ostensibly 637 umol salicylates/d (88 mg/d) for 2 d; salicylate excretions were 
268129 ^mol/24 h (37±4 mg/24 h, n=28) after a diet providing 0 mg salicylates/d for 2 d 
(13). Thus, Swain et al (AR Swain, RH Lobley, AS Truswell, unpublished observations, 
1985) recovered 86% (n=24) of dietary salicylates in urine. 
Swain et al (13-14) also reported 10-100-fold higher concentrations of total 
salicylates in foods than we (15-16) and others (9-12) did. A plausible interpretation of 
these discrepancies is that the assays used by Swain et al lacked specificity, and that 
substances other than salicylates were included in the salicylate figures. Estimated dietary 
salicylate intake data for the four subjects in table 2, using the data of Herrmann (10), 
Robertson and Kermode (11), and ourselves (15-16) may be somewhat underestimated due 
to the limited number of foods analyzed for salicylate, compared to the number of foods 
Swain et al analyzed (13-14). The correlation between salicylate excretion and dietary 
intake of fibre or vegetable protein that we found confirmed that plant foods are the major 
source of dietary salicylates. Therefore, we think the possible underestimation cannot be 
large because salicylate concentrations of the most important salicylate sources -plant foods-
have been given by Robertson and Kermode (11), Herrmann (10) and ourselves (15-16). 
If we correct our salicylate excretion data using a salicylate recovery of 100%, we estimate 
that even pure vegetable diets provided less than 43 umol (6 mg) salicylates/d. Even if most 
of this were in the form of acetylsalicylate, which is highly unlikely (15-16), these intakes 
are probably still too low to affect risk for coronary heart disease or colon cancer. 
At the same time, our data suggest that worries about adverse effects of dietary 
salicylates in children are unfounded. The data on salicylates in the Dutch Food Intolerance 
Databank (22) overestimate dietary salicylate intake because these data are derived almost 
entirely from Swain et al (13-14). Even if dietary salicylates affect behaviour, which is 
doubtful, our results suggest that amounts of salicylate in foods are so low that diet may 
be ignored as a source. 
We found that salicylate excretion in urine is a valid indicator for the intake of 
salicylates and that daily excretion of salicylates in urine is very low in subjects eating a 
variety of self-selected diets. We conclude that the amount of dietary (acetyl)salicylate is 
probably too low to affect disease risk. 
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Acetylsalicylic acid or 2-acetoxybenzoic acid (Fig 1) is the formal name of a drug 
commonly known as aspirin. Acetylsalicylic acid is effective as an anti-thrombotic drug in 
doses as low as 30 mg/d (1-3) Intake of acetylsalicylic acid is also associated with a 
decreased risk for colon cancer (4-5). Foods are thought to contain acetyl- and other 
salicylates (6-7), and Ingster et al suggested that intake of salicylates in foods might have 
contributed to the decline in cardiovascular disease mortality in the USA (7). If 
acetylsalicylic acid were present in foods, a diet rich in acetylsalicylic acid might have anti-
thrombotic and possibly anti-carcinogenic effects (6). 
Adverse effects of salicylates have also been described. Hypersensitivity may occur 
after medication containing salicylates, but improvement by a salicylate-free diet is highly 
unlikely (8). Feingold (9) suggested that elimination of artificial food colours and flavours, 
as well as of foods containing natural salicylates, improves behavioral disturbance of 
children. Although this could not be substantiated in properly controlled trials (10-11), 
belief in the efficacy of treatment with salicylate-free diets is firmly held (12). Contents of 
salicylates in foods are thus of interest. 
Data on salicylate contents of foods are scarce and contradictive (Table 1) (13-19). 
Salicylic acid (Fig 1) and other salicylates, mainly methyl esters and glucosides, have been 
isolated from a variety of plants (20). These salicylates can be hydrolysed to the parent 
salicylic acid (19). Consequently, food contents of total salicylic acid published include 
these to various extents. Robertson and Herrmann found salicylate contents of 0.03-3 mg/kg 
in fruits and vegetables, and 3-39 mg/kg in herbs and spices (15-18). Salicylate values 
reported by Swain et al were much higher: 0.8-23.9 mg/kg for fruits and vegetables, and 
62-2180 mg/kg for herbs and spices (13-14). Muller and Fugelsang reported salicylic acid 
concentrations ranging from 11.0-21.5 mg/L in Californian and other red and white wines. 
Concentrations in red wines were higher than in white (21). Venema et al (19) found 
salicylate contents comparable to data of Robertson and Herrmann (15-18): 0.03-0.87 mg/kg 
in fruits and vegetables, and 0.48-28.4 in herbs and spices. They also did not confirm the 
high contents in wine (22) reported by Muller and Fugelsang (21). 
ACETYLSALICYLIC ACID 
Fig 1: Structure of acetylsalicylic acid and salicylic acid. 
SALICYLIC ACID 
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Chapter S 
Acetylsalicylate contents of foods are important to study their possible anti-
thrombotic effects (1-3,6-7). Data on acetylsalicylate contents in foods are lacking. 
Qualitative analyses showed the presence of acetylsalicylate in 37 out of 56 foods studied 
by Swain (13). Acetylsalicylic acid is spontaneously hydrolysed to salicylic acid in aqueous 
solutions (23). Venema et al therefore developed a mild extraction method for 
acetylsalicylic acid in foods which prevented hydrolysis. Subsequently, they determined 
acetylsalicylate quantitatively in 30 foods previously reported to contain salicylates. 
Acetylsalicylate contents were lower than the limit of detection (0.02-0.2 mg/kg) in all 
foods studied (19,22). 
Differences in salicylate contents found in foods by various authors may be caused 
by differences in origin, processing, storage, or by differences in analytical methods. Swain 
(13-14) found a high natural variation amounting to 10-fold differences. Venema et al 
reported that this variation was much smaller (19). This excludes natural variation as a 
possible explanation for these discrepancies. Discrepancies in salicylate contents between 
extraction methods may arise through differences in the extent of liberation of matrix-bound 
salicylates. However, though Venema et al (19) used essentially the same extraction method 
as Swain (13-14), salicylate contents found were much lower (Table 1). There is reason to 
believe that HPLC separation and UV-detection as described by Swain et al was not 
specific enough, and that some other components may have co-eluted with salicylic acid. 
In contrast, Venema et al (19,22) used fluorescence detection thus gaining specificity over 
UV detection. 
It was recently shown that urinary excretion is a valid indicator of the intake of pure 
salicylic and acetylsalicylic acid (24). Thus, urinary salicylate excretion might be an 
indicator of the amounts of bio-available salicylates in the diet. Swain reported mean 
salicylate excretion (±SEM) of 114±6 mg/24 h (825±43 nmol/24 h) in urines of healthy 
volunteers consuming a diet providing 88 mg/d (637 umol) of salicylates for 2 d according 
to their food analyses. Mean salicylate excretions were 37±4 mg/d (268±29 umol/24 h) after 
a 2-d diet providing no salicylates (13-14). In contrast Janssen et al (24) found a median 
salicylate excretion in urine of only 1.4 mg/24 h, with a range of 0.8-1.6 mg/24 h (median 
10 umol, range 6-12) in 18 healthy subjects eating a wide variety of diets. The high values 
found by Swain et al (13-14) may be explained by co-elution of various compounds at the 
retention time of salicylate, as the HPLC-column used probably was too short and the flow 
may have been too high to obtain adequate separation. 
Based on the urinary salicylate excretion data of the volunteers eating a wide variety 
of diets, their food records, and Venema's salicylate contents of foods (19,22,24), it was 
estimated that even pure vegetable diets provide less than 6 mg (43 p.mol) of salicylates 
daily. If most of this were in the form of acetylsalicylate -which is unlikely (19,22)-, these 
intakes are probably still too low to affect disease risk. Ingster et al (7) proposed an 
increase in dietary salicylates in the US with time since 1960 reaching 90 mg/d/person in 
1960 and 125 mg/d/person in 1970. Those calculations, however, were based on salicylate 
contents published by Swain et al (14), which in our view overestimate dietary intake. We 
feel that true intakes of dietary salicylates in the US population are closer to 0-6 mg/d, and 
that the estimates of Ingster et al (7) are too high by almost two orders of magnitude. 
It is concluded that a normal mixed diet provides only 0-6 mg of salicylates daily, 
and no or almost no acetylsalicylic acid. Those amounts are probably too low to affect 
disease risk. At the same time, worries about adverse effects of dietary salicylates on the 
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behaviour of children are probably unfounded. 
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Abstract 
Intake of dietary flavonols and flavones is inversely associated with risk for 
cardiovascular disease. This might be due to effects on haemostasis, because flavonoids 
have been reported to inhibit platelet aggregation in vitro. We found that 2.5 umol/L of the 
flavone apigenin inhibited collagen- and ADP-induced aggregation in platelet-rich plasma 
and washed platelets by about 26%; the flavonols quercetin and quercetin-3-glucoside had 
no effect. To test this in vivo we fed 18 healthy volunteers onions providing 114 mg/d of 
quercetin glucosides, parsley providing 84 mg/d of apigenin glycosides -both expressed as 
aglycones-, or a placebo for 7 d each in a randomized cross-over experiment of 3x2 weeks. 
No effects were found on platelet aggregation, thromboxane B2 production, factor VII and 
other haemostatic parameters. We conclude that anti-aggregatory effects of flavonoids seen 
in vitro are due to concentrations that cannot be attained in vivo. Effects of dietary flavonols 
and flavones on cardiovascular risk are possibly not mediated by haemostatic parameters. 
Introduction 
Flavonoids are polyphenols compounds that occur ubiquitously in plant foods. 
Flavonols and flavones are subclasses of flavonoids (Fig 1) (1-4). Average daily intake with 
the Dutch diet was (5) for flavonols 16 mg of quercetin, 4 mg of kaempferol, and 1 mg of 
myricetin, and of flavones 1 mg of apigenin and 1 mg of luteolin. The intake of those 5 
dietary flavonoids was associated with a reduced risk for coronary heart disease or stroke 
in several (6-9), though not all (10-11) studies. 
R1 
X 
ÓH Ö 
Fig 1: Structure of flavonols and flavones. Flavonols: X=OH; quercetin: R,=OH, R2=H; kaempferol: 
R,=H, R2=H; myricetin: R,=OH, R2=OH. Flavones: X=H; apigenin: R,=H, R2=H; luteolin: R,=OH, 
R2=H. 
Two types of mechanisms have been proposed to explain this protective effect, 
namely inhibition of LDL-oxidation or inhibition of platelet aggregation (12,13). Results 
obtained by incubation of human platelets or animal cells with isolated flavonoids suggest 
that flavonoids inhibit platelet aggregation -probably by inhibition of cyclo-oxygenase 
activity-. Conflicting observations on the effects of flavonoids on in vitro platelet 
aggregation have been found (14-21). It has been stated that flavones are strong and 
flavonols moderate inhibitors of cyclo-oxygenase, and that flavonoid glycosides are less 
effective inhibitors than their aglycones —the sugar-free part of the flavonoid molecule— 
(14,21). The latter is relevant because flavonoids in foods are present mainly as glycosides 
(1), and we showed earlier that absorption of flavonoid glucosides is more effective than 
absorption of aglycones (22). Hollman et al found peak plasma quercetin concentrations in 
humans of 0.6 \xM (196 ng/mL) after consumption of 64.2 mg of quercetin from onions 
(23). Flavonoid concentrations used in in vitro studies ranged between 10 and 1000 uM 
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(14-21), which is thus 10 to 1000 times higher than plasma levels reached after oral intake. 
Data on plasma concentration of apigenin in humans are absent. There are thus several 
reasons why the effect of flavonoids on platelets in vivo might differ from those observed 
in vitro. 
Flavonoids may also affect the activity and/or the concentration of plasma 
coagulation or fibrinolysis factors (24-26). The formation of a thrombus in atherosclerotic 
arteries gives rise to the clinical state of acute coronary events, and is closely controlled by 
the haemostatic system, including coagulation and fibrinolysis (27,28). Several studies 
showed that plasma fibrinogen concentration is an independent risk factor of ischemic heart 
disease (29-31). Factor VII and plasminogen activity were associated with ischemic heart 
disease risk (30) and plasma PAI-1 activity was associated with increased risks of 
myocardial (re)infarction (31,32). 
We now carried out both an in vitro study and a dietary supplement study in 
healthy volunteers. In the in vitro study we investigated whether a test tube addition of 
flavonoids in the estimated physiological range (0-2.5 uM) inhibited in vitro platelet 
aggregation, and we included unphysiologically high concentrations of flavonoids (>2.5 
uM) to enable comparisons with published studies. In the dietary study we examined 
whether administration of foods rich in flavonoids affects platelet aggregation, coagulation 
and fibrinolysis in healthy volunteers. 
Subjects and methods 
Both protocols were approved by the Medical Ethics Committee of the Department 
of Human Nutrition, and were fully explained to the participants, who gave their written 
informed consent. Participants were all non-smokers. 
In vitro study 
Subjects 
Four men from the Department of Human Biology, Maastricht University, aged 24, 
29, 35, and 47 yrs, respectively, served as blood donors for the in vitro study. All were 
healthy, according to a medical questionnaire, and ate an ordinary western diet. None of the 
blood donors used any medication from 2 weeks preceding until the end of the study. 
Methods 
We investigated the effects on platelet aggregation of 6 concentrations (0, 0.25, 2.5, 
25, 250, and 2500 u.M) of pure quercetin-3-glucoside (Apin Chemicals LTD, Abingdon 
Oxon, United Kingdom), quercetin aglycone -i.e. quercetin without a sugar moiety-
(Quercetin Dihydrate, C. l.nr. 75670, Fluka Chemika AG, CH-9470, Buchs, Germany), 
apigenin aglycone (nr 10798, Fluka Chemika, Meppel, The Netherlands), and catechin ((+)-
catechin hydrate, Fluka Chemika, Meppel, the Netherlands). It was not possible to study in 
vitro effects of apigenin-glycosides, as these are not commercially available. Effects were 
studied both in platelet-rich plasma and in washed platelets to exclude possible effects of 
plasma factors on aggregation. Effects were not studied in whole blood as this is only stable 
during a short period. 
Indomethacin (1-7278; Sigma Chemie, St Louise Mo. 63178, USA), a specific 
inhibitor of the enzyme cyclo-oxygenase, was used as a positive control. Effects of final 
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Indomethacin concentrations of 0, 0.1, 1, 10, 100, and 1000 uM on in vitro platelet 
aggregation in platelet-rich plasma and washed platelets were tested using citrated blood of 
one of the donors. 
Aggregations in platelet-rich plasma were stimulated with final concentrations of 2 
|ag of collagen/mL (Collagen Horm, München, Germany) or 2.5 uM adenosine 5'-
diphosphate (ADP, A6521 Sigma Chemical, St Louis, USA). Aggregations in washed 
platelets were induced by 2.5 ug/mL collagen or 18 uM ADP. 
As polyphenols are known to bind proteins, catechin, a flavonoid with a high protein 
binding capacity (33) but hardly any effect on platelet aggregation or prostaglandin 
synthesis (14,20,34), served as a control for aspecific effects. 
Each donor gave blood 4 times within a period of 1-6 wks. Effects of apigenin, 
quercetin, quercetin-3-glucoside, and catechin were tested in random order for all 4 donors. 
Effects of the 6 different concentrations of each compound were tested on the same day in 
random order. 
After the participants had fasted during the night free-flowing venous blood was 
sampled without stasis (Strauss Kanüle, 1.2 mm Syringe, Luer, Wächterbach, Germany) 
with the subject in supine position. The first 3 mL of blood was discarded. Blood was 
collected into tubes prefilled with sodium-citrate solution (final concentration 10.9 mM, pH 
7.3; Merck BV, Amsterdam, The Netherlands). Platelet-rich plasma was prepared by 
centrifugation at 150-160g for 15 min at room temperature, and diluted with autologous 
platelet-poor plasma to a final concentration of 185*10' platelets/L. Washed platelets were 
prepared by mixing 5.8 mL tri-sodium-citrate 80 mM, citric acid 52 mM, and glucose 183 
mM Acid Citrate Dextrose (ACD) with 29.2 mL of blood; this was centrifugated for 15 min 
at 160 g, and platelet-rich plasma was removed. Subsequently 25 mL of the platelet-rich 
plasma was mixed with 1 mL ACD, centrifugated for 15 min at 610 g, and the platelet 
pellet was resuspended in 2 mL Hepes buffer (pH 6.6; NaCl 136 mM, KCl 2.7 mM, Hepes 
10 mM, MgCl2.6H20 2 mM, glucose 1 mg/mL, BSA 1 mg/mL), Hepes buffer was added 
to a total volume of 30 mL, and 1 mL ACD/15 mL was added. The suspension was 
centrifuged at 610 g for 15 min, and the platelet pellet was resuspended in Hepes buffer 
(pH 7.45). Glucose and BSA were added to the buffer just prior to use. 
After the first blood donation optimal doses of the stimuli collagen and ADP were 
determined per person using 5 uL blank solvent dimethylsulfoxide (DMSO, Fluka Chemie, 
Meppel, the Netherlands) instead of a flavonoid solution, under conditions as described 
below. The optimal stimulus doses, defined as the final concentrations leading to a maximal 
aggregation of 65%, were for the aggregations in platelet-rich plasma of the 4 donors 2.0, 
4.0, 2.0, and 4.0 ug collagen/mL, and 9.0, 5.0, 2.5, 2.5 uM ADP. The doses for aggregation 
in washed platelets of the 4 donors were 7.5, 7.5, 2.5, 7.5 ug collagen/mL, and 18.0, 18.0, 
18.0, 6.0 uM ADP, respectively. These doses were used throughout. 
For each aggregation measurement 400 |o.L of the diluted platelet-rich plasma or 
washed-platelets were incubated in an aggregometer at 37° C, at 1000 rpm (Chronolog 
Corporation, Havertown, PA, USA). Flavonoids were dissolved in DMSO, and 5 uL were 
added to the platelets to produce final concentrations of 0, 0.25, 2.5, 25, 250, and 2500 uM. 
Ten (iL of collagen suspension or ADP were added exactly 10 min after addition of the 
flavonoid. We added fibrinogen (final concentration 0.5 mg/mL; fraction 1, type 4, bovine 
plasma, Sigma Chemie, Brunschwig, Amsterdam, the Netherlands) during the ADP-induced 
aggregation of washed platelets. The change in percentage of transmitted light was 
monitored continuously during 7 min. Light transmitted was set at 100% for platelet-poor 
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plasma and Hepes buffer, and 0% for platelet-rich plasma and the washed platelet 
suspension. 
Aggregation measurements were completed within 2 h after blood sampling. We 
found in earlier studies (unpublished observations) that platelets were stable during this 
period. Platelets were always handled in plastic material and at room temperature. Maximal 
aggregation was calculated for all measurements. For ADP-induced aggregations maximal 
aggregation of the first wave was used as outcome variable. Maximal aggregation on 5 uL 
of solvent DMSO using optimal individual stimulus concentrations was chosen as 100%. 
Mean maximal aggregation values for each flavonoid concentration was calculated by 
taking the mean value of the 4 donors. 
Dietary supplement study 
Subjects 
Ten men and 12 women were recruited through announcements in the University 
newspaper and posters in student dormitories. One man was excluded because of elevated 
alanine-amino and gamma-glutamyl transferase. One woman withdrew on her own accord. 
Nine men and 9 women were selected at random from the remaining 20 subjects. One man 
dropped out during the first week of the study, due to personal reasons unrelated to the 
study. A women who had participated in the screening replaced him; she started at day 7 
of the study. All 18 volunteers successfully completed the study. Participants were healthy 
based on a medical questionnaire. All had normal values for urinary protein and glucose, 
haematocrit, haemoglobin, white blood cell and platelet count, mean red cell volume, 
plasma alanine-amino transferase, plasma gamma-glutamyl transferase, serum creatinine, 
prothrombin and activated partial thromboplastin time. Mean age (±sd) was 25+8 years, and 
body mass index was 22±1 kg/m2. 
Methods 
Design: We investigated the effects of daily consumption of flavonoid-rich dietary 
supplements on parameters for haemostasis in a randomised placebo-controlled multiple 
cross-over study (fig 2). All subjects participated simultaneously. Participants consumed 
supplements daily during weeks 2, 4, and 6. Week 1 served as run-in, and weeks 3 and 5 
as wash-out periods. Supplements were given in random order. 
days 
measurements: 
blood sampling 
body weight 
diary 
24-h recalls 
run-in 
1 
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Fig 2: Design of the randomized placebo-controlled cross-over study of 3x2 wks. Ten women and 8 men 
consumed 400 g bouillon daily with 220 g of onions, 4.9 g of parsley, or nothing as a placebo for 7 d. 
All treatments were given to every subject in random order. 
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Supplements: Supplements consisted of 400 g of bouillon, to which was added either 220 
g of cooked yellow onions (Favorit MSP, class II 60-80 mm, Luctor, Dronten, The 
Netherlands), 4.9 g of dried Western-European parsley (Verstegen Specerijen, Rotterdam, 
The Netherlands), or nothing as a placebo. Onions, parsley, and bouillon powder (Maggi 
Bouillonkorrels, Nestlé Foodservice Catering, Amsterdam, The Netherlands) were bought 
in one batch just before the study, and stored in the dark at 4 °C. The onions were thinly 
peeled 1 week before the study started, cut into pieces of 8x8x8 mm (Robot-Coupe S.A., 
Montceau-en-Bourgogne, France), heated in portions of 600 g in a microwave oven for 5 
min at 800 W or 7 min at 500 W, mixed, and heated for another 4 min at 800 W, or 5 min 
at 500 W. Portions of 220 g were weighed out, and stored at -20°C. Onions were thawed 
in the dark at room temperature overnight before consumption. Before the study started the 
parsley was mixed, weighed out in portions of 4.9 g, and stored in the dark at room 
temperature until consumption. Bouillon was prepared each day before consumption using 
16.7 g of bouillon powder per kg of boiling water; portions of 400 g were weighed out, and 
stored in the dark at 4°C. Duplicate portions of the supplements were prepared daily, and 
stored at -20 °C until analyses (35). The onion supplement contained 114±3 mg (377±10 
umol; n=15, mean±sd) and the placebo 0.01510.004 mg (0.05±0.01 umol; n=6) of 
quercetin. The parsley supplement contained 84±6 mg (n=15) apigenin. 
In wks 2, 4, and 6 subjects came to the department daily in fasting status between 
7.30-9.00 a.m. on working days, and 8.00-10.00 on weekend days to consume their 
supplements. Parsley and onions were mixed with the bouillon just prior to consumption. 
The onion-soup was heated for 6 min at 800 W, or for 7 min at 500 W; the parsley-soup 
and placebo bouillon were heated for 4.5 min at 500 W, or 3.5 min at 800 W. Participants 
were not allowed to eat or drink anything, except (mineral)water until 2 h after consumption 
of their supplements. 
Food consumption, physical activity and medication: Participants were urged not to 
consume any fruits and vegetables containing more than 15 mg quercetin or apigenin per 
kg and any beverages containing more than 4 mg/L (i.e. apples, endive, beans, broccoli, 
celery, cherries, cloves, grapes, leek, onions, parsley, tea, tomato, wine) (35-38), or any 
fatty fish. Subjects were asked to maintain their normal eating and drinking habits and 
physical activity levels during the study. They were instructed to avoid all regular and 
homoeopathic medicines, and vitamin and mineral supplements from 1 month preceding the 
study until the end of the study. Use of oral contraceptives was permitted. Participants were 
supplied with Paracetamol which could be used for pain relief. Subjects were urged to 
record health complaints, medications used, and any deviations from their normal physical 
activity and dietary habits in a diary. We determined body weights of the participants, and 
checked the diaries weekly; food intake was measured 3 times (wks 2, 4, and 6) using 24-h 
recalls (39) (fig 2). The habitual intake of energy of the subjects was on average 9.3±2.7 
MJ/d (2214±642 kcal/d, meanlsd), of which 31 ±9% was provided by fat, 14±3% by 
protein, 53±10% by carbohydrate, and 1+3% by alcohol, with no changes during the study. 
Mean body weight decreased by 0.3+1.4 kg during the study. Subjects did not consume any 
fatty fish. There was no evidence from the diaries of changes in physical activity patterns 
or any deviations that might have affected the results. One subject took iron tablets 
(Ferrofumaraat, 3 tablets of 200 mg daily) from day 33 until the end of the study because 
of low hemoglobin values. Except for the Paracetamol supplied by us no medication was 
used. All participants denied having used acetylsalicylic acid from 1 month preceding until 
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the end of the study. 
Blood sampling: Blood samples were taken on days 14, 28, and 42 (fig 2) as described 
above. About 25 mL of blood were drawn, at 90 minutes after the participant had consumed 
the supplement. The participant was lying down for 20 min before, until the end of 
venepuncture. Blood was drawn into tubes containing a final concentration of 10.9 mM 
sodium-citrate. Samples for coagulation and fibrinolysis measurements were put on ice 
immediately. 
Analyses: Immediately after venepuncture one mL of citrated blood was incubated in a 
prewarmed aggregometer (37 °C) and stirred at 1000 rpm. Exactly 5 min later 10 uL of 
collagen suspension (final concentration 2 ug/mL) was added and whole blood aggregation 
using an impedance method was recorded for 10 min on a computerized system. Maximal 
aggregation was measured to study effects of the supplements on platelet aggregation under 
most physiological conditions. 
Platelet-rich plasma containing 250*10' platelets/L was prepared as described earlier 
(40). Some diluted platelet rich plasma was frozen in fluid nitrogen, and stored at -80 °C 
for determination of flavonoid concentrations. HPLC separation was used combined with 
fluorescence detection for determination of quercetin (Hollman et al, unpublished 
observations), and with UV detection for apigenin concentrations (35). 
For each aggregation 400 uL platelet-rich plasma was incubated in a prewarmed (37 
°C) aggregometer and stirred at 1000 rpm. Exactly 5 min later 10 uL of collagen (final 
concentration 2.0 jig/mL) or ADP (final concentration 1.5 and 3.0 uM) were added to 
induce aggregation. The change in percentage of transmitted light was monitored 
continuously during 10 min and maximal aggregation was calculated as described for the 
in vitro study. 
Maximally stimulated thromboxane B2 production in platelet-rich plasma was 
measured as described earlier (40) as a specific measure of active cyclo-oxygenase present. 
All samples of one subject were analyzed within one run. 
Immediately after blood sampling plasma for measurements of coagulation and 
fibrinolysis parameters was separated by centrifugation at 1500 g for 20 min at 4°C . It was 
divided into aliquots, snap-frozen in liquid nitrogen, and stored at -80°C. Factor VII and 
plasminogen activity were determined using a laser-nephelometric centrifugal ACL-200 
analyzer (Instrument Laboratory, Milano, Italy). Factor VII clotting time was determined 
in a standard one-stage assay: plasma samples and factor Vll-deficient plasma were mixed, 
the clotting process was initiated, and clotting time was measured using PT-Fibrinogen and 
thromboplastin from Instrumentation Laboratory (IJsselstein, The Netherlands), and Factor 
VII from Organon Technica (Oss, The Netherlands). Plasminogen activity was determined 
according to the test manufacturer's instructions using CO ATEST antiplasmine and 
Streptokinase from Chromogenix (Amsterdam, The Netherlands). Blood for a normal 
plasma pool was donated by 40 healthy volunteers. Factor VII and plasminogen results were 
expressed in percentages relative to values for this pool. Standards for factor VII and 
plasminogen measurements were derived from BIOPOOL (Haemostasis Reference Plasma, 
Kordia, Leiden, The Netherlands). Plasma fibrinogen concentrations were determined using 
a STA II coagulation Analyser (STA-fibrinogen, Diagnostica Stago, Boehringer, Mannheim, 
Germany): a fixed surplus of thrombin was added to diluted platelet-poor plasma samples, 
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and the clotting time was measured of a series of dilutions of a human plasma pool with 
a known fibrinogen concentration. Standards for fibrinogen measurements were derived 
from Boehringer (STA-Preciclot I & II, Boehringer, Mannheim, Germany). PAI-activity was 
measured using a Chromogenic Assay (Spectrolyse/pL PAI, Biopool, Umea, Sweden). 
Plasminogen and factor VII measurements were done in duplicate; fibrinogen and PAI-1 
measurements were done in simplo. 
Statistics: We checked the data for normality using residual analysis (41). Effects of onions 
and parsley were analyzed using the General Linear Models of the Statistical Analyses 
System (cc=0.05) (42), with subject and treatment as class variables. A period term was 
introduced into the model to check for time effects, and a treatment-by-period interaction 
term to check for carry-over effects. Subsequently 95%-confidence intervals were calculated 
for effects of onions and parsley. 
Results 
In vitro study 
Indomethacin 1 |amol/L inhibited maximal collagen-induced aggregation in human 
platelet-rich plasma by 67%, and in washed platelets by 74%; 1000 umol/L inhibited 
aggregation in platelet-rich plasma by 98%, and in washed platelets by 82%. ADP-induced 
aggregation was hardly affected. Catechin inhibited collagen- and ADP-induced aggregation 
in platelet-rich plasma only at a concentration of 2500 uM (Fig 3-4). Results in washed 
platelets were similar to results found in platelet-rich plasma (data not shown). 
Apigenin in a concentration of 2.5 uM inhibited collagen-induced aggregation in 
platelet-rich plasma by 26% (SEM 17%), and ADP-induced aggregation by 19% (SEM 
17%). Apigenin 25 p.M inhibited collagen-induced aggregation by 31%, whereas 2500 \iM 
inhibited aggregation by 91%. Apigenin 25 uM inhibited ADP-induced aggregation in 
platelet-rich plasma by 31, and 2500 uM inhibited aggregation by 83%. In platelet-rich 
plasma 2500 p.M of the flavonol quercetin inhibited collagen- and ADP-induced aggregation 
by about 95%, whereas lower concentrations were ineffective. Concentrations of 0.25 and 
2.5 uM of the flavonol-glucoside quercetin-3-glucoside did not affect platelet aggregation; 
concentrations of 25, 250 and 2500 uM decreased collagen-induced platelet aggregation, 
but ADP-induced aggregation was not affected. Effects on aggregation in washed platelets 
were comparable with those in platelet rich plasma (Fig 3-4). 
Dietary supplement study 
No adverse reactions to the supplements were reported, although some people had 
difficulties in consuming the amount of onions at once. One subject consumed only part of 
the onion supplement at one occasion; the left-over contained 29 mg of quercetin. Subjects 
consumed negligible amounts of flavonol- or flavon-rich products during the study. 
Concentrations of quercetin in platelet-rich plasma were 1.48±0.39 uM (4471117 
ng/mL) 90 min after consumption of onions, and 0.02±0.01 uM (5+4 ng/mL) after placebo. 
Contents of apigenin in platelet-rich plasma were all below the limit of detection of 1.1 \iM 
or 330 ng/mL. 
Daily treatment with 220 g of cooked onions or 4.9 g of dried parsley for 7 d did 
not affect collagen-induced platelet aggregation in whole blood or platelet-rich plasma, 
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ADP-induced platelet aggregation in platelet-rich plasma, thromboxane B2 production, 
platelet number, factor VII, plasminogen and PAI-I activity, or fibrinogen concentration 
(Table 1). There were no treatment sequence or time effects. 
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Discussion 
In vitro study 
The in vitro study showed that a test tube addition of 2.5 umol/L of apigenin inhibits 
collagen- and ADP-induced aggregation in human platelets, whereas quercetin and 
quercetin-3-glucoside did not. Flavonoid concentrations of 25 to 2500 umol/L, inhibited 
platelet aggregation in vitro. The dietary supplement study, however, showed that 
administration of large amounts of foods rich in apigenin or quercetin-glucosides did not 
affect platelet aggregation or other haemostatic parameters in healthy volunteers. 
We carried out highly standardized aggregation measurements in both studies. 
Published in vitro studies were not always strictly standardized as to platelet number and 
optimal stimulus concentration for each donor. Also, the experimental conditions varied 
from one study to another, which probably explains the large variety in outcome (14-21). 
To check the validity of the in vitro aggregation measurements, Indomethacin was 
used as a positive and catechin as a negative control. As expected Indomethacin -a specific 
inhibitor of cyclo-oxygenase (43)- inhibited in vitro platelet aggregation induced by 
collagen, but not by ADP. We therefore conclude that our assay was able to detect specific 
inhibiting effects on cyclo-oxygenase activity in both platelet-rich plasma and washed 
platelets. The in vitro study showed that concentrations of 0.25 and 2.5 uM of catechin -
which has a high affinity for proteins- did not affect collagen- or ADP-induced platelet 
aggregation, although unphysiologically high concentrations (25-2500 uM) did (Fig 3,4). 
The latter may be an a-specific inhibiting effect, as flavonoids readily bind to proteins (34). 
Thus, it is not very likely that a-specific protein-binding explains the results for apigenin 
at physiological concentrations. 
Dietary supplement study 
Values of the haemostatic parameters measured in the dietary supplement study after 
treatment with placebo were in the normal range for healthy volunteers (Table 1). Data 
from the diaries, body weights, and 24-h recalls did not reveal any confounding effects. All 
18 subjects ate the supplements under our supervision. Plasma quercetin values after 
treatment with placebo indicated negligible dietary quercetin contents in the background 
diets. Plasma quercetin concentration after treatment with the onion supplement indicate that 
quercetin was absorbed. We bought all onions, parsley and bouillon before the study to 
exclude differences between batches. We stored all onion supplements at -20° C, and the 
parsley in dark at room temperature to diminish changes in composition of the onions. We 
prepared all supplements in a standardized way (see Methods section) to prevent differences 
in composition of the supplements during the study. 
Comparison with results of earlier studies 
Gryglewski and coworkers reported stimulation of cyclo-oxygenase activity by 
addition of quercetin or rutin to ram seminal vesicle microsomes (17). In contrast, results 
of other structure-function studies suggest that flavones such as apigenin are strong 
inhibitors, and flavonols such as quercetin are moderate inhibitors of cylo-oxygenase. Those 
studies also suggested that glycosylated compounds are less potent inhibitors of cyclo-
oxygenase than their aglycones (14,21). A major drawback of in vitro studies done earlier 
is that only the effects of unphysiologically high flavonoid contents (>10 uM) were studied 
(14-21). It was recently shown that plasma peak quercetin concentrations in humans were 
51 
Chapter 6 
0.6 uM after consumption of 64 mg quercetin from onions (23). Although no data on 
apigenin absorption are available our data show that plasma peak apigenin concentrations 
in humans range between 0 and 1.1 uM. We found that the flavon apigenin did inhibit 
collagen-induced aggregation in vitro only at concentrations of 2.5 uM or higher both in 
platelet-rich plasma and in washed platelets, whereas quercetin and its glucoside -the form 
in which it appears in foods and in which it is probably absorbed (22)- did not affect 
collagen- or ADP-induced aggregation. The quercetin concentration in platelet-rich plasma 
after onion consumption was comparable with data reported earlier (23). Apigenin 
concentration in platelet-rich plasma could not be quantified because of the high limit of 
detection (330 ng/mL, 1.1 uM). Thus it is unclear whether apigenin was absorbed. It is 
unlikely that apigenin absorption was inhibited by dietary proteins as the subjects were not 
allowed to eat or drink anything until 2 h after consumption of the supplements, and as the 
supplements contained hardly any protein. The plasma concentration of quercetin suggests 
that these measures were adequate. It is possible that plasma peak values and elimination 
curves of apigenin are different from quercetin (23) and that blood sampling at a different 
time point would reveal apigenin concentrations higher than the detection limit. In any case, 
if apigenin is absorbed, the prolonged supplementation would ensure interaction with the 
blood components. Epidemiological studies showed that the inverse association between 
dietary flavonoid intake and coronary heart disease risk was strongest with quercetin (9). 
Besides average daily dietary intake of quercetin was high (16 mg), compared to intake of 
apigenin (1 mg) in the Netherlands (5). 
In accordance with our in vitro data, no effect of consumption of apigenin- or 
quercetin-rich foods was found on collagen-induced aggregation in whole blood and 
platelet-rich plasma, on ADP-induced aggregation in platelet-rich plasma, on thromboxane 
production, and on other haemostatic variables (Table 1). This indicates that daily 
consumption of large amounts of quercetin- or apigenin-rich foods may not be effective as 
inhibitors of cyclo-oxygenase activity or platelet aggregation in human volunteers. 
We think that the treatment periods of the dietary supplement study were long 
enough to detect possible effects on blood platelet function. Blood platelets have a mean 
life time of 7-10 days; therefore treatment during 7 d with very high daily doses of 
flavonoids must be sufficient to find effects on platelet aggregation and thromboxane B2 
production. We earlier showed in similar volunteers that even 3 mg/d of acetylsalicylic acid 
inhibited maximally stimulated platelet thromboxane production by 39±8% (40). Meade et 
al (30) showed that mean fibrinogen concentration in women who died from ischemic heart 
disease was 3.38 g/L (95% confidence interval 3.11 to 3.66), whereas the concentration in 
survivors was 3.31 g/L (95% confidence interval 3.25 to 3.37). Contents of clotting factor 
VII as percentage of standard were 120% (95% confidence interval 108 to 132%) in 
subjects with ischemic heart disease, and 113% (95% confidence interval 110 to 115%) in 
survivors (30). Hamsten et al showed (31) in a prospective study that plasma PAI-1 
concentrations are positively associated with increased risk of myocardial infarction among 
survivors of a first myocardial infarct: PAI-1 concentrations of patients with reinfarction 
were 1.6 times the values of patients with uneventful courses. In conclusion we think that 
our study group was large enough to detect relevant effects on thromboxane production and 
platelet aggregation in our study (Table 1). We might have missed small biologically 
relevant effects (29-32) of dietary flavonoids on the coagulation and fibrinolytic parameters 
measured (Table 1); this should be examined in a larger study population. 
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Results of our supplement study agree with results from the dietary supplement study 
of Srivastava et al (44). They found no effects of consumption of 70 g of raw onions daily 
for 7 d on platelet thromboxane production in 5 healthy volunteers: the mean effect of 
onion consumption on thromboxane production was 95 pmol/mL serum (sd=756, n=5). 
These authors could however have missed biologically significant effects due to the small 
study sample, the low dose, and the large variation in the outcome variable. We did not find 
any effects in a larger group consuming 220 g of onions daily. 
Hertog et al showed that average daily intake with the Dutch diet was 16 mg/d of 
quercetin and 1 mg/d of apigenin (5). In our dietary supplement study the participants 
consumed very high doses of flavonoids: 114 mg/d of quercetin and 84 mg/d of apigenin. 
We think consumption of higher doses is impractical in a normal mixed diet. 
Conclusions 
Suggestions for an anti-aggregatory effect of flavonoids are based on the in vitro use 
of concentrations that cannot be attained in vivo by dietary consumption. Reported effects 
of dietary flavonoids on coronary heart disease risk are possibly not mediated through 
collagen- or ADP-induced platelet aggregation or cyclo-oxygenase activity. We cannot 
exclude small biologically relevant effects of dietary flavonoids on known risk indicators 
for coronary heart disease from the coagulation cascade or fibrinolytic system. The latter 
should be examined in a larger population. 
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Consumption of ginger 
(Zingiber Officinale Roscoe) 
does not affect ex vivo platelet 
thromboxane production in humans 
Janssen PLTMK, Meyboom S, van Staveren WA, de Vegt F, Katan MB. 
Consumption of ginger {Zingiber Officinale Roscoe) does not affect ex vivo platelet 
thromboxane production in humans. 
Eur J Clin Nutr 1996;50:772-4. 
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Abstract 
Ginger (Zingiber Officinale Roscoe) has been claimed to exert an anti-thrombotic 
effect in humans as ginger extracts inhibit cyclo-oxygenase activity of platelets in vitro. 
Effects of ginger consumption on ex vivo platelet function, however, are contradictory. We 
therefore investigated whether daily consumption of raw or cooked ginger decreases platelet 
cyclo-oxygenase activity as assessed by ex vivo maximally stimulated platelet thromboxane 
B2 production. We carried out a randomized placebo-controlled cross-over study of 3x2 
weeks. Eighteen healthy volunteers aged 22+3 y (mean+sd) participated in the study; there 
were no drop-outs. Subjects consumed 15 g of raw ginger root, 40 g of cooked stem ginger, 
or placebo daily for 2 weeks each. We took fasted venous blood samples and measured 
thromboxane B2 production in maximally stimulated platelet-rich plasma at days 12 and 14 
of each treatment period. Mean decrease in thromboxane production relative to placebo was 
1±9% for ginger root, and -1±8% for stem ginger, with no effect of treatment order 
(p=0.984). We cannot confirm the putative anti-thrombotic activity of ginger in humans. 
Introduction 
We are interested in natural aspirin-like factors in foods as such factors may partly 
explain the relatively low incidence of cardiovascular disease in oriental countries (1-3). 
It has been suggested that ginger exerts an anti-thrombotic activity (4), because 
ginger extracts inhibit platelet aggregation and thromboxane B2 production in vitro (5,6). 
However data on effects of ginger consumption on blood platelet function, and specifically 
on cyclo-oxygenase activity, are scarce and contradictive (7-10). 
We therefore performed a study investigating the effect of daily consumption of raw 
ginger root or cooked stem ginger on platelet cyclo-oxygenase activity as assessed by 
maximally stimulated ex vivo platelet thromboxane production in healthy volunteers. 
Subjects and methods 
Subjects 
We recruited 24 subjects through announcements in the University newspaper and 
posters in student dormitories. We excluded one subject because of elevated values for 
serum creatinine and alanine amino transferase, and one because of a marginally low value 
for mean red cell volume. We selected 9 men and 9 women at random from the remaining 
22 subjects; all 18 volunteers completed the study. 
Participants were healthy based on a medical questionnaire, none suffered from 
urinary protein or glucose, or high blood pressure. All had normal values for haematocrit, 
haemoglobin, mean red cell volume, erythrocyte sedimentation rate, plasma alanine amino 
transferase, gamma-glutamyl transferase, and creatinine, platelet count, thrombin time, 
prothrombin time, and activated partial thromboplastin time. The volunteers did not smoke 
and did not use any regular or homoeopathic medication. Mean age (±sd) was 22±3 years 
and body mass index was 22±2 kg/m2. 
We urged the participants not to consume any products containing ginger, or any 
fatty fish, and to maintain their normal eating and drinking habits and physical activity 
levels during the study. We instructed subjects to avoid all regular and homoeopathic 
medicines from 1 month preceding the study until the end of the study. We supplied them 
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with paracetamol which could be used as a pain medication. We urged subjects to record 
times of consumption of the supplements, health complaints, medications used, and any 
deviations from their normal physical activity and dietary habits in a diary. 
The protocol was approved by the Medical Ethics Committee of the Department of 
Human Nutrition and was fully explained to the participants, who gave their written 
informed consent. 
Methods 
We investigated the effects of daily consumption of ginger root and stem ginger 
relative to placebo on ex vivo maximally stimulated platelet thromboxane production. We 
carried out a randomised multiple cross-over study of 3 consecutive 2-week periods during 
which each participant consumed all supplements in different order. All subjects participated 
simultaneously. 
Supplements consisted of 125 g of vanilla custard (Coberco, Arnhem, The 
Netherlands), containing either 15 g of Brazilian ginger root (Toko Rinus, Nijmegen, The 
Netherlands), 40 g of stem ginger (Ambition, Polak Import, Rotterdam, The Netherlands), 
or no ginger as a placebo. The custard served to mask the pungent taste of ginger. Stem 
ginger and ginger root originated from two separate batches. We bought vanilla custard at 
a local supermarket every few days and preserved all products in the dark at 4° C. We 
prepared all supplements in a similar way during the whole study. 
We prepared supplements with raw ginger each working day: we thinly peeled 
ginger roots, cut them into small pieces (Magimix, Micave BV, Utrecht, The Netherlands), 
and weighed out portions of 15 g. We prepared the placebo and stem ginger supplements 
3 times a week. We rinsed the stem ginger, cut it into pieces, and divided it into portions 
of 40 g. We weighed out portions of 125 g of vanilla custard. 
Participants came to the Department on working days to consume their supplements 
of raw ginger, and took their supplements home for the weekends on Fridays. We handed 
out the placebo and stem ginger supplements 3 times a week. We supplied all supplements 
in closed boxes containing cooling elements, and instructed all subjects to keep their 
supplements in a refrigerator and to mix the custard with the ginger immediately prior to 
consumption. 
We weekly determined body weights of the participants using a digital scale (Berkel 
ED 60-T, Rotterdam, The Netherlands), checked the diary and measured food intake using 
a24-h recall (11-12). 
Venous blood was sampled using a butterfly needle system (Becton Dickenson, 
Meylan, France) after an overnight fast on days 12 and 14 of each treatment period while 
the participant was lying down. We discarded the first 3 mL of blood to prevent activation, 
and drew the next 18 mL slowly into 3.8% sodium-citrate tubes 1:10 v/v (Sarstedt, Etten-
Leur, The Netherlands). We prepared platelet-rich plasma by centrifugation (Sigma, 
Osterode, Germany) at room temperature for 10 min at 200 g, removed the platelet-rich 
plasma, prepared platelet-poor plasma by centrifuging the residual blood for 15 min at 
2000g, and normalized the platelet-rich plasma to 250*109platelets/L by adding autologous 
platelet-poor plasma. We counted platelets before and after dilution (Coulter, Coulter 
Corporation, Miami, FL) and stimulated 450 uL of normalized platelet-rich plasma with 
arachidonic acid (final concentration 1.5 mM) (Bio Data Corporation, Horsham, USA) in 
an aggregometer (37° C, 900 rpm; Payton Aggregation Module, Salm en Kipp, Breukelen, 
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The Netherlands). We then took out 50 uL of the aggregate exactly 10 min after the 
addition of arachidonic acid, added it to 950 uL buffer containing 9 g/L NaCl, 0.01 mol/L 
EDTA, 3 g/L bovine gamma-globulin, 0.005% Triton-X-100, and 0.05% sodium-azide in 
50 mM phosphate buffer, pH 6.8 (NEN Research Products, Du Pont, Boston, MA), 
immediately submerged the samples in liquid nitrogen, and stored them at -80 °C until 
analysis. We measured thromboxane B2 production in duplicate using a thromboxane B2 
[,25I] RIA kit (NEN Research Products, Du Pont, Boston, MA). We analyzed all samples 
from a particular subject within one run. Within-person variation over a 2-day period was 
12%) after placebo, 10%> after raw and 8%> after cooked ginger treatment. 
Plasma of 2 healthy volunteers who had not used any medication for at least 1 
month served as quality control for thromboxane measurements. We once sampled venous 
blood from these volunteers, and stimulated ex vivo platelet thromboxane production in 
platelet-rich plasma as described above. We stored aliquots of aggregates, and measured 
thromboxane B2 production at every radio-immuno assay. Within-assay variation for 
thromboxane measurements was 9%; between-run variation was 9%. 
We checked the data for normality using residual analysis (13). We averaged the 
2 values of thromboxane production obtained for each subject on days 12 and 14 of each 
treatment period, and analyzed differences in thromboxane production, body weight, and 
intake of energy and macronutrients between treatments using the General Linear Models 
of the Statistical Analyses System (14) with subject and treatment as class variables; we 
used p<0.05 to indicate significant difference. We introduced a period term into the model 
to check for time effects, and a treatment-by-period interaction term to check for carry-over 
effects. Values in the text are means±sd. 
Results 
Daily treatment with 15 g of ginger root or 40 g of stem ginger for 14 d did not 
affect maximum ex vivo platelet thromboxane production (p=0.616). Mean thromboxane B2 
production was 2994±566 nmol/10" platelets after treatment with raw ginger, 3044±546 
after cooked ginger, and 3045±609 after placebo. The average effects on platelet 
thromboxane B2 production relative to placebo were -1+9% (+sd) on raw ginger, and 1±8% 
on cooked ginger. There was neither a treatment sequence (p=0.984), nor a time effect 
(p=0.932). 
The habitual diet of the subjects as measured by 24-h recall supplied on average 
11+5 MJ/d (2629±1195 kcal/d, meanlsd), of which 32±9% was fat, 13±3% protein, 53+8% 
carbohydrate, and 2±3% alcohol. Mean body weight increased by 0.3+1.1 kg during the 
study. There were no changes in intake of macronutrients (p=0.12 for fat; 0.10 for 
carbohydrate; 0.73 for protein; 0.84 for alcohol) and energy (p=0.23) between treatment 
periods. Subjects did not consume any fatty fish. All participants consumed the raw ginger 
supplements under our supervision on working days and reported that they had consumed 
all other supplements at home. There was no evidence from the diaries of changes in 
physical activity patterns or any deviation that might have affected the results. 
No adverse reactions to the supplements were reported. One subject took 7 tablets 
of paracetamol spread over 3 consecutive days because of toothache, and another took 2 
tablets/d for 2 consecutive days because of a headache. One subject took 2x20 mg of 
temazepam during treatment with stem ginger, and 4x20 mg during treatment with ginger 
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root. Temazepam is a sedative and was taken because of a sleeping disorder unrelated to 
the study. All participants denied having used acetylsalicylic acid from 1 month preceding 
the study until the end of the study. 
Discussion 
We found that daily consumption of large amounts of ginger did not affect ex vivo 
platelet thromboxane production in healthy volunteers. Data from the diaries as well as data 
on food consumption did not reveal any confounding effects of medication, physical activity 
levels, or dietary patterns. We bought all ginger at once before the study to exclude 
differences between batches, stored the products in the dark at 4° C to diminish changes in 
composition of the ginger, and prepared the supplements in a standardized way (see 
Subjects and methods section) to prevent differences in composition of the supplements 
during the study. The compounds known to affect in vitro platelet activity (gingerols, 
shogaols, zingerone) generally exist in the fleshy centre of the rhizome (15); we used these 
parts of the ginger in the raw ginger supplements. We earlier showed in similar volunteers 
that even as little as 3 mg/d of acetylsalicylic acid decreased maximally stimulated ex vivo 
thromboxane B2 production by 39+8% (16); we could thus calculate that the power of this 
study was 90% to pick up an effect of 6% or more. 
Our data disagree with results of Dorso (7) and Verma et al. (10). Dorso (7) 
described a total inhibition of stimulated ex vivo platelet aggregation after consumption of 
large amounts of ginger-grapefruit marmalade; this study was done in only one subject, and 
the result may be due to chance. Verma et al (10) showed that consumption of butter 
increased platelet aggregation induced by adenosine diphosphate (ADP) and epinephrine, 
and that this increase was neutralized by simultaneously administering 5 g of powdered 
ginger for 7 d. Our results are in accordance with ex vivo results of Lumb (8) and 
Srivastava (9). Lumb (8) found no effects of consumption of 2 g of dried ginger on 
bleeding time and whole blood platelet aggregation. Platelet aggregation and bleeding time 
measurements, however, are much less specific for determination of platelet cyclo-
oxygenase activity than measurement of platelet thromboxane production; results of Verma 
et al (10) may indicate that ginger consumption affects secretion in platelets (17). Lumb (8) 
could have missed possible long-term effects of ginger consumption, as he studied effects 
of only a single dose. It is highly unlikely that we missed possible long-term effects, as 
blood platelets have a mean life-time of 7-10 d. This indicates that our daily treatment with 
high doses of ginger during 14 d must have been long enough to trace effects on platelet 
thromboxane production. Srivastava (9) found no significant effect of consumption of 5 g/d 
of raw ginger for 7 d on serum thromboxane production in 7 healthy volunteers, but the 
power of Srivastava's study was too low to pick up relevant effects due to the large 
variation in the outcome variable. 
We fed the participants 15 g of raw ginger root or 40 g of stem ginger. These are 
very high doses. Consumption of higher doses is impractical because of the pungent taste. 
If any inhibitors of cyclo-oxygenase activity are present in ginger they are probably not 
absorbed or are rendered ineffective during first-pass metabolism in the body. We think it 
is unlikely that daily consumption of raw or cooked ginger affects platelet cyclo-oxygenase 
activity. However, it remains worthwhile to search for other possible aspirin-like agents in 
foods. 
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In this chapter the answers to the questions listed in Chapter 1 will be given, 
conclusions will be drawn and suggestions for future research will be given. 
Acetylsalicylic acid, haemostasis and thrombosis 
We showed that even 3 mg/d of acetylsalicylic acid (the amount previously thought 
to be present in a normal mixed Western diet) decreased ex vivo thromboxane B2 formation 
in healthy subjects (Chapter 2). Based on these results we concluded that quantitative data 
on acetylsalicylate in foods and their possible anti-thrombotic effects deserved closer 
investigation. 
The total salicylate contents we found were, however, only 0-1 mg/kg in vegetables 
and fruits, and 3-28 mg/kg in herbs and spices. Acetylsalicylate contents were lower than 
the limit of detection (0.02 mg/kg for fresh products and 0.2 mg/kg for dried products) in 
all foods studied (Chapter 3). 
We found that urinary excretion was a valid indicator for the intake of pure 
acetylsalicylic and salicylic acid. Median 24-h salicylate excretion in subjects eating a wide 
variety of diets was low: 1.4 mg (range 0.8-1.6; median 10 umol, range 6-12). Values 
increased with the fibre content of the diet, suggesting that vegetable foods are the main 
sources of bio-available dietary salicylates (Chapter 4). 
Based on the food analyses (Chapter 3) and the urinary excretion data (Chapter 4) 
we estimate that even pure vegetable diets provide less than 6 mg/d (43 umol/d) of total 
salicylates. If most of this were in the form of acetylsalicylate, which is highly unlikely, 
these intakes are probably too low to affect coronary heart disease risk (1-2). It was recently 
suggested that dietary salicylate intake might have contributed to the decline in 
cardiovascular disease mortality in the USA (3). Those calculations were however based 
on salicylate contents published by Swain et al (4-5). We think (Chapter 3-5) Swain et al's 
data highly overestimate dietary salicylate intake. On the other hand, our data (Chapter 3-5) 
suggest that worries about the adverse effects of dietary salicylates on, for example, the 
behaviour of children may be unfounded (6) (Chapter 5). 
Flavonoids, haemostasis and thrombosis 
Concentrations of 2.5 uM of the flavone apigenin inhibited collagen- and ADP-
induced platelet aggregation in vitro, whereas the flavonols quercetin and quercetin-3-
glucoside had no effect. We found no effects of daily consumption of large amounts of 
onions (quercetin-) or parsley (apigenin-rich) on platelet aggregation, thromboxane 
production, or other haemostatic parameters in healthy subjects. 
We conclude that claims for the anti-aggregatory effects of flavonoids (7-8) are 
based on the in vitro use of concentrations (9-11) that cannot be attained in vivo (12). Our 
in vitro and ex vivo findings suggest that reported effects of dietary flavonoids on coronary 
vascular disease risk are probably not mediated through collagen- or ADP-induced platelet 
aggregation or cyclo-oxygenase activity. We might have missed small biologically relevant 
effects on known risk indicators for coronary heart disease from the coagulation cascade 
or the fibrinolytic system. This should be examined in a larger population (Chapter 6). 
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Ginger, haemostasis and thrombosis 
In our study consumption of raw or cooked ginger did not affect ex vivo platelet 
thromboxane production in healthy volunteers. The test used did not confirm the putative 
anti-thrombotic effect of ginger consumption in humans (13-15). 
We think consumption of higher doses than we used in our study is impractical 
because of the pungent taste. If any inhibitors of cyclo-oxygenase activity are present in 
ginger, they are probably not absorbed or are rendered ineffective during the first pass 
metabolism in the body (Chapter 7). 
Conclusions 
The main question of this thesis was: Do dietary non-nutrients (salicylates, 
flavonoids, ginger-components) affect haemostatic parameters in humans? Our answer 
to this question is: we estimate (based on the salicylate analyses in foods and our salicylate 
excretion data) that the contents of acetylsalicylate in diets is nil or negligible, which is 
probably too low to affect coronary heart disease risk. Besides, the tests used did not 
confirm the putative anti-thrombotic effects of consumption of ginger and flavonoid-rich 
foods in healthy subjects. 
There is reason to believe that the separation and detection methods Swain and 
coworkers used (4-5) were not specific enough, and that some other components may have 
co-eluted with salicylic acid, leading to an overestimation of dietary salicylate intake. The 
salicylate contents we found, using a highly specific and sensitive method, were 10-100 
times lower and comparable to values found by Robertson and Herrmann (16-19). Although 
Robertson and Herrmann published their salicylate data during 1981-1990 in peer-reviewed 
international journals, only the data of Swain et al (4-5) were mentioned in a recent review 
on the salicylate contents of foods and their putative effects on health (20). We conclude 
from this that the belief in the presence and effects of foods high in salicylates is firmly 
held, but unjustly so. A possible explanation for this strong belief in the results of Swain 
et al is that their data were published in the Journal of the American Dietetic Association 
(4), which may be frequently read by dieticians, nutritionists, and physicians. In contrast 
to this, the data of Herrmann and Robertson were published in journals with main topics 
on food analyses and food composition (16-19). It is likely that these journals are mainly 
read by food scientists or analytical chemists. Furthermore, one of Herrmann's articles (17) 
was written not in English but in German, which might have diminished the accessability 
of the information. 
Based on our findings we also conclude that worries about the adverse effects of 
dietary salicylates on, for example, the behaviour of children may be unlikely (6) (Chapter 
3-5). 
Suggestions 
Our data on the salicylate contents of foods should be added to salicylate databanks 
and used in advice on diet and hyperactivity. I suggest that researchers publish their data 
in peer-reviewed English journals, frequently read by the people they want to reach to 
increase the chance that their message reaches the proper audience. 
Information on the metabolism of flavonoids in humans needs further investigation 
63 
Chapter 8 
to further understanding their possible effects on health (7-8). Possible effects of dietary 
flavonoids on coagulation or fibrinolytic parameters should be examined in a larger study. 
Claims for anti-aggregatory effects of flavonoids (7-11) are based on the in vitro use of 
concentrations that cannot be attained in vivo (Chapter 6) (12). Therefore we suggest that 
studies on dietary effects on human health should not be limited to in vitro experiments 
only, but also carried out in humans as much as possible. We recommend the use of 
physiological conditions, especially of in vitro studies to increase the generalizability of the 
results. In addition we would like to stress the importance of standardization of analyses 
of haemostatic parameters to increase the comparability of studies. The latter is extremely 
important as analyses of haemostatic parameters are prone to interferences and as a golden 
standard for measuring haemostasis is absent yet. 
As coronary heart disease is the most important cause of death and disease in the 
Western world (21), it remains worthwhile to search for possible anti-thrombotic 
compounds in foods. 
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Hart- en vaatziekten, zoals een hartaanval en beroerte, zijn een groot probleem voor 
de gezondheid in welvarende landen. Het dagelijks slikken van kleine hoeveelheden 
acetylsalicylzuur, de werkzame stof in aspirine, helpt hart- en vaatziekten te voorkómen. 
Bloedplaatjes, gespecialiseerde bloedcellen, spelen hierbij een belangrijke rol. Ze helpen bij 
de bloedstolling, dus het afsluiten en herstel van wondjes. Als bloedplaatjes echter te veel 
aan elkaar, of aan de wand van een bloedvat plakken, kunnen ongewenste bloedpropjes 
ontstaan. Dit kan leiden tot verstoppingen van het bloedvat en dus tot hart- en vaatziekten. 
Acetylsalicylzuur remt het cyclo-oxygenase in de bloedplaatjes. De bloedplaatjes maken dan 
minder thromboxaan en plakken daardoor minder aaneen. Acetylsalicylzuur voorkomt zo 
verstoppingen in een bloedvat en daarmee het ontstaan van hart- en vaatziekten. 
Aspirine-achtige stoffen komen mogelijk ook van nature in voedingsmiddelen voor. 
Een voeding rijk aan deze stoffen zou dan kunnen helpen om hart- en vaatziekten te 
voorkómen. Australische onderzoekers schatten dat een normale Westerse voeding per dag 
3 mg acetylsalicylzuur bevat, maar exacte hoeveelheden waren onbekend (Hoofdstuk 1). 
Wij vonden dat de thromboxaanproductie door bloedplaatjes van gezonde mensen daalde 
na het slikken van 3 mg acetylsalicylzuur per dag (Hoofdstuk 2). Dit kan erop wijzen dat 
zelfs een kleine hoeveelheid aspirine helpt om hart- en vaatziekten tegen te gaan. Wij 
bepaalden daarom de hoeveelheid acetylsalicylzuur in Nederlandse voedingsmiddelen. Ook 
werd de hoeveelheid salicylzuur, de moeder-verbinding van aspirine, gemeten. Salicylzuur 
zou mogelijk hyperactiviteit of overgevoeligheid veroorzaken. We vonden geen 
acetylsalicylzuur in de onderzochte voedingsmiddelen. De hoeveelheid salicylzuur was laag: 
10-100 keer lager dan de Australiërs vonden. Hun methode was echter minder specifiek en 
nauwkeurig (Hoofdstuk 3). Vervolgens slikten 6 mensen 10 mg acetyl- of salicylzuur. We 
vonden hiervan 80% terug in urine, verzameld gedurende 24 uur. De hoeveelheid in urine 
lijkt dus een goede maat voor de inname. We vonden dat mensen met uiteenlopende 
voedingsgewoonten slechts een paar mg salicylzuur per 24 uur uitplasten (Hoofdstuk 4). 
Dit wijst erop dat een mens via voeding hooguit enkele mg acetyl- of salicylzuur per dag 
binnenkrijgt, waarschijnlijk te weinig om de gezondheid te beïnvloeden (Hoofdstuk 5). 
Er waren aanwijzingen dat flavonoïden, natuurlijke stoffen in plantaardige 
voedingsmiddelen, beschermen tegen hart- en vaatziekten door de thromboxaan-vorming 
en de klontering van bloedplaatjes te remmen. We namen bloed af bij gezonde mensen en 
voegden hieraan flavonoïden toe in concentraties zoals ze ook in het lichaam voorkomen. 
Het flavonoïd apigenine ging het aan elkaar plakken van bloedplaatjes tegen, het flavonoïd 
quercetine had geen effect. Vervolgens aten 18 gezonde mensen per dag 220 g ui of 4,9 g 
gedroogde peterselie. Ui bevat veel quercetine en peterselie veel apigenine. We vonden geen 
effecten op het aan elkaar plakken van de bloedplaatjes en de thromboxaan-vorming 
(Hoofdstuk 6). Flavonoïden beïnvloeden dus mogelijk niet de activiteit van bloedplaatjes. 
Gember vermindert mogelijk ook de activiteit van bloedplaatjes. Wij vonden echter 
geen effect op de thromboxaan-vorming bij 18 gezonde vrijwilligers die dagelijks grote 
hoeveelheden rauwe of gekookte gember aten gedurende 2 weken (Hoofdstuk 7). 
Wij concluderen (Hoofdstuk 8) dat de hoeveelheid (acetyl)salicylzuur in voeding 
waarschijnlijk te laag is om hart- en vaatziekten te voorkomen of om hyperactiviteit en 
overgevoeligheid te veroorzaken. We konden niet aantonen dat het dagelijks eten van veel 
gember, ui en peterselie eenzelfde beschermend effect heeft als acetylsalicylzuur. 
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Alle mensen die mij de afgelopen jaren op welke manier dan ook geholpen hebben, 
wil ik hierbij graag bedanken. 
Lieve Michel, dankzij jou weet ik dat er veel belangrijkere dingen in het leven zijn 
dan werk. Het doet me goed dat we het zo fijn hebben samen en dat we eindelijk ons Thuis 
hebben. Dank je wel. 
Dit proefschrift draag ik op aan mijn moeder.' Lieve mam, jij bent iemand uit 
duizenden. Bescheiden maar met onuitputtelijke energie en respect verdiep jij je telkens in 
het wel en wee van anderen. Ik vind het knap dat je als leek toch duidelijk wist te krijgen 
wat er in het project gebeurde. Ik hoop dat jouw oprechte belangstelling voor de medemens 
een voorbeeld mag zijn voor anderen. Dank je wel. 
Mijn paranimfen -Angela Schulz en Marie-Louise Heijnen- en Martine Alles: jullie 
verdienen een bijzonder woord van dank. Het doet me goed drie zulke lieve mensen te 
kennen. Angela, lieve maat, fijn dat ik altijd bij je terecht kan. Ik ben blij dat we nu weer 
dichter bij elkaar wonen; dat maakt het plannen van T wat makkelijker. Lieve Marie-
Louise, ik heb veel hulp van je gehad de afgelopen jaren. Het is altijd fijn met je te praten 
over belangrijke dingen in het leven. Ik hoop dat we elkaar in de toekomst veel zullen 
horen en zien. Lieve Martine, dank je wel voor de fijne tijd samen op 003. Ik heb goede 
herinneringen aan alle gesprekken die we samen hadden. Dat we zaten op de kamer van de 
O-resultaten mocht de pret niet drukken. Laten we onze schema's goed bewaren!! 
Mijn promotoren en co-promotor bedank ik voor hun bijdragen aan het project. 
Martijn, van je kritische kijk op dingen heb ik vooral bij het schrijven veel geleerd. Wija, 
ik stel het op prijs dat je mijn promotor wilde blijven, ondanks dat het onderzoek in een 
andere richting ging dan gepland. Ronald, ik vind het jammer dat je niet vanaf het begin 
mijn co-promotor mocht zijn. Ik ben blij dat ik steeds voor inhoudelijke zaken bij je terecht 
kon. Je begeleiding was voor mij erg prettig en waardevol. Ik wil je ook bedanken voor het 
beschikbaar stellen van de apparatuur en het mogelijk maken van de in vitro studie. 
Peter Hollman en Dini Venema (RIKILT-DLO), jullie hebben gezorgd voor het 
opzetten en valideren van de methode om salicylaten in de monsters te meten. Dit was een 
hele klus en ik ben er trots op dat het jullie gelukt is. Ik hoop van harte dat vele mensen 
over de salicylaat-analyses zullen lezen, en dat nu eindelijk eens enkele verhalen de wereld 
uit geholpen kunnen worden. Peter, je hebt een groot deel van mijn begeleiding op je 
genomen en was altijd bereid om me te helpen en mee te denken. Je kwam steeds met 
goede ideeën en kan die op een prettige en heldere manier overbrengen. Dini, dank je wel 
voor alle werk dat je verricht hebt binnen dit project en voor het voorbereiden en uitvoeren 
van alle salicylaat-analyses. 
Graag wil ik de bijzondere inspanningen van ons lab vermelden: Jan Harryvan, 
Robert Hovenier, Joke Barendse, Paul Hulshof en Marga van der Steen, hartelijk bedankt 
dat jullie met zoveel inzet de bijzondere bloedafnames hebben gedaan. Robert en Jan, ik 
heb goede herinneringen aan onze aggregatie-training op de vakgroep Humane Biologie, 
Maastricht. Ik kijk met plezier terug op de zware, maar geslaagde meetdagen tijdens de 
proeven. Zonder jullie had ik het niet gered en was het nooit zo gezellig geweest: starti-di-
motorri voor de prp-p-pees! Joke, ik heb geluk gehad met zo'n fijne collega als jij. Je hebt 
me erg geholpen. Ik hoop dat we elkaar in de toekomst nog vaak zullen spreken. 
Frank Cox en Jo Wierts (Vakgroep Humane Biologie, Universiteit van Maastricht): 
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jullie wil ik graag bedanken voor jullie gastvrijheid en de vele uren die jullie aggregerend 
doorbrachten om de flavo-jongens in vitro te testen. Frank, bedankt voor de aggregatie-
cursus, en voor het brengen en installeren van de apparatuur. 
Many thanks to the participants of all ASPRO-studies. It would not have been 
possible to do these studies without you! Ook de bloeddonoren van de vakgroep Humane 
Biologie: hartelijk bedankt voor jullie medewerking! 
De Nederlandse Hartstichting, de Stichting Onderzoek Voeding en Gezondheid 
(SOVG) en de Landbouwuniversiteit Wageningen wil ik graag hartelijk danken voor de 
financiering van het project. Dit proefschrift werd gedrukt met financiële middelen van de 
Nederlandse Hartstichting en de Landbouwuniversiteit; hartelijk dank hiervoor. 
Graag wil ik enkele mensen uit het Academisch Ziekenhuis Utrecht bedanken. 
Allereerst van de afdeling Haematologie: Anneke Starkenburg, Bep de Weerd, Mariene 
Mommersteeg, Elly Voorter en Gertie Gorter, bedankt voor jullie hulp bij de aggregaties 
van de pilot-studie en bij de thromboxaan-analyses. Ik vond het prettig om bij jullie te 
werken. Jan-Willem Akkerman, dank voor het beschikbaar stellen van de apparatuur en 
voor je suggesties. Jaap-Jan Zwaginga, bedankt voor het beoordelen van de medische 
vragenlijsten en voor je suggesties. Medewerkers van het laboratorium van de polikliniek, 
bedankt voor de bloedafnames van de ASPRO-1. 
Femmie de Vegt, Almi Hanselman, Marjanne Straatman en Itske Zijp: jullie hebben 
tijdens jullie afstudeervak bergen werk voor me verzet. Bedankt daarvoor! 
Saskia Meyboom en Esther Reichman, dank jullie wel voor het coördineren van het 
voedselconsumptieonderzoek. Saskia, bedankt voor het uitdenken van de supplementen. 
Paulan Polet, Gerty Gielen en Paul van der Molen: jullie brachten voor mij de 
proefpersonen van de ASPRO-1 in alle vroegte heen en weer naar het AZU. Fijn dat ik 
steeds op jullie kon rekenen. 
Michel Buisman, RIKILT-DLO, bedankt voor het uitvoeren van de flavonoïd-
analyses in plasma en supplementen. Alle mensen van het lab van Peter Hollman: bedankt 
voor jullie gastvrijheid. Daan van der Heide, vakgroep Fysiologie van Mens en Dier, 
bedankt voor het beschikbaar stellen van het isotopenlab voor de thromboxaanmetingen. 
Daan Kromhout en Edith Feskens, RIVM, Bilthoven, bedankt voor jullie suggesties. 
Norbert Duif, hartelijk dank voor het nakijken van de medische vragenlijsten. Susan 
Parren, dank je wel voor het corrigeren van een deel van de Engelse teksten. Mary Dijks-
hoorn, Lous van der Loos en Martie Wagenaar, bedankt voor de gesprekken die ik met 
jullie had. Ik heb er veel aan gehad! 
Nicole Zimmermanns, Rob Urgert en Lucie Viet: gezellig dat jullie mijn 
kamergenoten waren. Ans Schoumans, Ben Schölte, Hannie van Oosten, Marie Jansen, 
Jeanne de Vries, Peter Zoek en Jan Burema, dank voor jullie hulp. 
Als laatste maar zeker niet het minst belangrijk: pap, Marian, Frances, Wies, Désirée, 
Hulda en Ank, bedankt voor al jullie goede zorgen! 
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© Tekst/Muziek: Dirk Witte 
Als je op de tafel kijkt, 
Van den dokter, van den dokter, 
Wat daar zoo voor defligs prijkt; 
Als je op de tafel kijkt, 
Is het eerste wat we zien: 
Aspirine, aspirien! 
Aspirine voor je beenen, 
Aspirine voor je buik, 
Tegen blaren op je teenen. 
En als je je pols verstuikt. 
Aspirine voor je armen, 
Voor je nek en voor je darmen, 
De soldaatjes, één voor één, 
Gaan met aspirine heen. 
's Morgens staan ze kwart voor acht 
Voor den dokter, voor den dokter, 
Alles wat maar moet op wacht, 
Staat al klaar om kwart voor acht; 
Negen krijgen van de tien: 
Aspirine, aspirien! 
Aspirine voor de goeierds 
Na een slapeloozen nacht, 
Aspirine voor de knoeierds, 
Die verlangen: "vrij van wacht!" 
Aspirine alleen kan baten 
Voor of eieren en voor soldaten, 
Voor fourier en voor sergeant, 
En voor 't paard van d 'Adjudant. 
Als we weer eens burger zijn, 
Gaan we nooit meer naar den dokter, 
Zelf genezen w'alle pijn. 
Als we eerst maar burger zijn 
Koopen w'elk een pond of tien 
Aspirine, aspirien! 
Aspirine voor je oudje, 
Aspirine voor je hond, 
Aspirine voor je vrouwtje, 
Als er weer een kleintje komt. 
Aspirine zal niet hind'ren 
Voor je kanarie en voor je kind'ren; 
Dokters kan ik niet meer zien: 
Ik zweer trouw aan d'aspirien. 
© 
G. Alsbach & Co. - Flevolaan 41 - Naarden - Holland. 
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